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Coronary heart disease is a major cause of death in Western society. Many studies
have demonstrated the importance of lipid metabolism in the deterioration in cardiac
function and the development of lethal arrhythmias during ischaemia.
It has been suggested that a TAG-NEFA (triacylglycerol-non-esterified fatty acid)
"wasteful" cycle exists in the ischaemic heart and that increased operation of the cycle
depletes ATP (adenosine triphosphate) supplies for the energy dependent ion pumps,
disturbs membrane potentials and therefore causes arrhythmias. The aim of this thesis
was to quantify energy wastage due to the operation of the TAG-NEFA cycle in the heart
during oxygen deprivation. The hypoxic, perfused rat heart was used as the
experimental model. Cannulation of the pulmonary artery allowed anaerobic sampling
of coronary effluent for measurement of blood gases, and therefore calculation of oxygen
uptake. Glycerol release was used as an index of TAG breakdown. Lactate production
and tissue concentrations of ATP, CP (creatine phosphate), glycogen, a-
glycerophosphate, glycerol and TAG were measured. The rate of TAG-NEFA cycling
could therefore be calculated.
The influence of severity of hypoxia on the rate of TAG-NEFA cycling was studied.
A positive correlation between severity of hypoxia and energy utilization by the
operation of the cycle was demonstrated. However, even during severe hypoxia
(10%O2, 85%N2, 5%CC>2), the proportion of the total ATP produced during hypoxia
utilized in the operation of the cycle was small (less than 7%).
The influence of age, fasting (48h) and obesity on the operation of the cycle during
normoxia and hypoxia was also studied. A five-fold difference in myocardial TAG
concentration was found to be of little importance in determining the rate of the TAG-
NEFA cycle. The rate of cycling was reduced in fasted rats.
The role of endogenous catecholamines in the metabolic changes induced by hypoxia
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was investigated. Myocardial noradrenaline release could not be stimulated by oxygen
deprivation. In contrast to isoprenaline-stimulated glycerol release, hypoxia stimulated
glycerol release could not be inhibited by p-adrenoceptor blocking agents. Furthermore,
depletion of endogenous catecholamines by pretreatment of rats with 6-
hydroxydopamine caused only a 30% reduction in hypoxia-stimulated glycerol release.
The validity of the use of glycerol release as an index of myocardial lipolysis was
questioned. Hypoxia-stimulated glycerol release was unaffected by the presence of
0.2% defatted albumin in the perfusate, suggesting that product inhibition caused by the
presence of elevated tissue NEFA concentrations was not rate limiting. Nicotinic acid, a
compound possessing antilipolytic properties in adipose tissue caused partial inhibition of
isoprenaline-stimulated glycerol release. However, the drug had no effect on hypoxia-
stimulated glycerol release in the heart. Labelling of myocardial TAG stores by infusion
of radiolabelled glycerol and measurement of specific activity of glycerol released from
the heart during normoxia, isoprenaline infusion and hypoxia inferred the presence of
glycerokinase activity in the tissue and the existence of more than one TAG pool in the
heart.
In conclusion: 1) The operation of the TAG-NEFA cycle during hypoxia does not
appear to cause a major drain on high energy phosphate supplies in the heart. 2) The rate
of cycling is independent of myocardial TAG concentrations. 3) Glycerokinase activity
can be demonstrated in the rat heart. 4) Glycerol release during hypoxia is mediated by
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Coronary heart disease is a major cause of death in Western society. A large
proportion of deaths due to acute myocardial infarction happen within the first hour after
the onset of symptoms (Kuller 1962, Armstrong et al. 1972).
Myocardial ischaemia is a common cause of arrhythmias, or disturbances in the normal
electrical rhythm of the heart. Ischaemia can be defined as an imbalance between the
supply of oxygenated blood and the oxygen requirements of the myocardium. Lethal
arrhythmias are the most common cause of sudden cardiac death (Armstrong et al. 1972).
Myocardial ischaemia may be caused by coronary artery thrombus formation (Davies
and Thomas 1985) or spasm (Olivia and Beckinbridge 1977) against a background of
coronary heart disease. In situations such as these, the ensuing inadequate blood supply
is inevitably accompanied by biochemical changes within the tissue. Many experimental
studies have implicated biochemical changes within the heart in the development of
ischaemic injury and arrhythmias.
The provision of energy for the maintenance of the function of the heart depends
largely on oxidative metabolism, and during ischaemia there is a shift from p-oxidation
of fatty acids to both aerobic and anaerobic glucose utilization. This is significant in that
it is an oxygen sparing activity, as fatty acid oxidation requires more oxygen per mole of
ATP produced than does glucose (P/O ratio 2.85 compared with 3.15 for glucose).
Furthermore, oxidation of fatty acids in the heart requires even more oxygen than would
be expected on the basis of the P/O rato (Mjos 1971). The switch to increased glucose
oxidation during ischaemia is therefore potentially beneficial, and increased fatty acid
oxidation is likely to be deleterious to the already compromised myocardium.
This section reviews briefly some aspects of the metabolism of the heart during
normoxia, hypoxia and ischaemia with particular emphasis on TAG and NEFA
metabolism in the heart.
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1.2. Substrate metabolism of the heart during normoxia.
It is not the intention to give a comprehensive review of the metabolism of the heart.
For the sake of clarity a summary of the relevant aspects of the normal, ischaemic and
hypoxic heart is given. The mammalian heart is in a constant state of mechnical and
catabolic flux. The major purpose of the metabolism of the heart is to provide sufficient
energy in the form of ATP to balance the requirements of contractile function. Calcium
ions act as the physiological regulator of muscle contraction. Depolarization of the cell
membrane activates an inward Ca++ current, which triggers release of Ca++ from the
sarcoplasmic reticulum. The released Ca++ binds to troponin and causes conformational
changes which are transmitted to tropomyosin and then to actin. Contractile force is
thus generated, and ATP is concomitantly hydrolysed.
Bing (1954), using coronary sinus catheterization and comparing the composition of
the arterial and coronary venous blood established that glucose, free fatty acids and
lactate are the major substrates for energy metabolism of the heart. Uptake of tritiated
palmitate was inhibited by 5.5mM lactate (Rose and Goresky 1977), indicating the
preferential use of lactate by the heart. The myocardium is also able to use fuels such as
pyruvate, acetate, ketone bodies and amino acids, although even when the supply of these
substrates is raised, their relative contribution is too small for them to be major
myocardial sources of energy. In addition, the heart may also use its internal stores of
energy i.e. glycogen and lipid.
Substrate utilization in the heart is critically dependent on both substrate availability
and hormonal status (Drake-Holland 1983). Though the amount of heat liberated per
mole of fat oxidized (approximately 2.6 kcal) is more than twice that per mole of
carbohydrate oxidized (approximately 0.7 Kcal). This is because more oxygen is
required to oxidize a gram of fat than a gram of carbohydrate.
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1.2.1. Glucose metabolism.
The metabolism of glucose in the heart has been extensively reviewed (Opie 1968). A
brief summary is given here.
Uptake of glucose into the heart is controlled by a stereospecific glucose carrier which
displays saturation kinetics (Morgan and Neely 1972). The carrier requires no energy
for transport because the glucose concentration in the extracellular space is so much
higher than in the cytosol (Opie 1984). Hormones such as insulin, adrenaline and Cortisol
increase transport of glucose into the heart (Morgan et al. 1961, Neely et al. 1967,
Taegtmeyer et al. 1980). In the normal myocardium, cardiac work, availability of
substrates, plasma insulin and glucose concentration act in concert as the most important
factors in regulating glucose uptake (Taegtmeyer 1988). The amount of glucose taken
up by the heart is very small compared with the plasma glucose concentration.
Measurement of glucose uptake is therefore subject to large errors and its estimation is
limited by the precision of the glucose assay being used. Samples must be analyzed
numerous times in order to obtain accurate results.
During normal, oxidative metabolism, breakdown of glucose via glycolysis yields
pyruvate which is then broken down aerobically in the citric acid cycle. Under
normoxic conditions, the rate of glycolyis is limited by the high levels of citrate and ATP
formed during oxidative metabolism. When fatty acids are oxidized, the glucose taken
up by the heart is increasingly converted to glycogen. This is known as the "glucose
sparing" effect of fatty acids. Conversion of 1 molecule of glucose to 2 molecules of
pyruvate yields 2 molecules of ATP. The reactions involved in glycolysis and its
regulation are summarized in Fig 1.1.
Phosphofructokinasel (PFK1) is the most important regulatory enzyme in the control
of glycolysis under normal conditions. ATP elicits allosteric control of PFK1 by binding
to a highly speccific regulatory site on the enzyme which is distinct from the catalytic
8








































site. The inhibitory action of ATP is reversed by AMP, and so the activity of the enzyme
increases when the ATP/AMP ratio is lowered.As in the liver, ffuctose-2.6-bisphosphate,
synthesized by phosphorylation of fructose-6-phosphate by PFK2 is a potent activator of
PFK1, acting in a synergistic fashion with AMP to maintain PK1 in its active form, and
increasing the affinity of PFK1 for fructose-6-phosphate. However, unlike in the liver,
PFK2 in the heart is not activated by cAMP-dependent protein kinase (Rider and Hue
1986). PFK1 is also allosterically regulated by citrate, an early intermediate in the citric
acid cycle. A high level of citrate indicates that biosynthetic precursors such as NAD+
and ATP are abundant and so additional glucose should not be degraded for this purpose.
The control of PFK1 by citrate plays a role in the control of selection of fuels by the
myocardium by decreasing rates of glucose metabolism in the presence of NEFA, ketone
bodies or pyruvate. Citrate inhibits PFK1 by enhancing the inhibitory effect of ATP.
The oxidation of NADH is facilitated by the transfer of electrons to dihydroxyacetone
phosphate which is thereby reduced to a-glycerophosphate by a-glycerophosphate
dehydrogenase, resulting in the formation of NAD+. a-glycerophosphate then diffuses
through the outer mitochondrial membrane and is reoxidized by an FAD+-linked a-
glycerophosphate dehydrogenase located on the external side of the inner mitocondrial
membrane. The electrons are passed to coenzyme Q by a reductase complex located
within the inner mitochondrial membrane. The dihydroxyacetone phosphate formed in
this way is free to return to the cytoplasm and serve as an electron acceptor for the
reoxidation of another molecule of NADH.
Another important regulatory enzyme of glycolysis is glyceraldehyde-3-phosphate
dehydrogenase (Mochizuki and Neely 1979). This enzyme is sensitive to the
NADH/NAD+ ratio in the cell, being activated by a decreased NADH/NAD+ ratio and
vice versa.
Pyruvate kinase converts phosphoenolpyruvate to pyruvate, with the concomitant
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production of ATP. This enzyme is subject to allosteric inhibition by ATP and
activation by fructose-1,6-diphosphate and phosphoenolpyruvate.
Under normoxic conditions, most of the pyruvate formed during glycolysis is
transported into the mitochondrial matrix by a specific carrier where it enters the citric
acid cycle and is subsequently oxidized (Denton and Halestrap 1979).
In the mitochondria, pyruvate dehydrogenase catalyzes the conversion of pyruvate to
acetyl coA, allowing entry into the citric acid cycle. The pyruvate dehydrogenase
complex may exist in an active or inactive form and is covalently regulated by
phosphorylation/dephosphorylation. Acetyl CoA and NADH, the products of the
oxidation of pyruvate, inhibit the enzyme complex. These inhibitory effects are reversed
by CoA and NAD+ respectively. Pyruvate dehydrogenase is also activated by AMP and
inhibited by GTP.
Pyruvate may also be converted to lactate by the enzyme lactate dehydrogenase.
Under normoxic conditions, the activity of this enzyme is limited by the low
NADH/NAD+ ratio of the cell and entry of pyruvate into the citric acid cycle. However,
some lactate is formed from pyruvate (Huckabee 1958).
1.2.2. Glycogen metabolism.
Excess glucose entering the myocyte is stored in the form of high molecular weight
glycogen as large granules in the cytoplasm. This substrate store is in a constant state of
turnover (Opie 1968). Glycogen metabolism is separated from glucose metabolism in
that glucose-6-phosphate is formed in the first step in the breakdown of glucose, whereas
glucose-1-phosphate is formed from glycogen. Glycogen and glucose breakdown
converge in the formation of glucose-6-phosphate to glucose-1-phosphate. Two
different pathways exist for glycogen synthesis and breakdown.
The key enzyme in glycogen synthesis is glycogen synthetase. This enzyme exists in
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an inactive phosphorylated D form and an active dephosphorylated I form. Conversion
of the active to the inactive form is ATP dependent and catalyzed by glycogen synthetase
kinase. Glycogen synthetase kinase itself can be activated by cAMP and hence is under
hormonal control. Inactive phosphorylated glycogen synthetase may become
enzymatically active in its phosphorylated form in the presence of high intracellular
concentrations of glucose-6-phosphate i.e. when glucose uptake into the cell is increased
or when the glycolytic rate is decreased. Dephosphorylation of glycogen synthetase is
controlled by glycogen synthetase phosphatase. This phosphatase is inhibited by
glycogen. Thus when glycogen levels are high, glycogen synthetase will remain in its
inactive (phosphorylated) form.
Glycogen degradation is catalyzed by glycogen phosphorylase. This enzyme may be
present in an activated form as phosphorylase a and an inactivated form as phosphorylase
b. The conversion of phosphorylase b to phosphorylase a is covalently regulated by
phosphorylation by the action of phosphorylase kinase. Calcium ions are required for
formation of phosphorylase a (Werth et al. 1982). Phosphorylase b is also active in the
presence of high concentrations of AMP, which acts allosterically by binding to a
binding site on the enzyme and hence altering its conformation. Glucose-6- phosphate
also inhibits phosphorylase b, presumably by binding to another site.
Extracellular hormones such as adrenaline, noradrenaline and glucagon transform both
glycogen synthetase and glycogen phosphorylase into a form which becomes less
sensitive to intracellular metabolically regulated control mechanisms. Thus, activities of
the enzymes involved in glycogen synthesis and breakdown are controlled in a concerted
manner by hormonal as well as intracellular mechanisms.
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Figure 1.2. The regulation of glycogen metabolism.
1.2.3. Non-esterified-fatty acid (NEFA) metabolism.
NEFA metabolism was originally thought to be unimportant in the heart as plasma
levels are low in comparison with glucose and TAG. However, despite the low plasma
concentrations of NEFA, their rate of turnover in the heart is high. Long chain non-
esterified fatty acids (NEFA) are insoluble in water and are transported in the blood
bound to albumin or in the form of triacylglycerol (TAG) complexed to hydrophilic
lipoproteins (Frederickson and Gordon 1958). Short chain NEFA are water soluble and
therefore may be transported in an unbound form in the blood.
Uptake of NEFA by the myocardium increases as the plasma concentration of NEFA,
or more correctly, the NEFA:albumin molar ratio rises (Carlsten et al. 1961, Evans et al.
1963, Vik-Mo et al. 1979, Miller et al. 1976). Interaction of the NEFA-albumin complex
with sites at the luminal membranes of the endothelial cells lining the myocardial
capillaries has been proposed (Little et al. 1986). The nature of transport of NEFA from
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the endothelial cells into the myocytes has not been completely elucidated. Simple
diffusion due to the steep concentration gradient from plasma to sarcoplasm, or
transendothelial and transinterstitial space transport, facilitated by fatty acid binding
proteins (FABP) and albumin respectively have been put forward as possible
mechanisms. The process of NEFA transport into the myocyte appears to be energy
independent (Spector 1971).
Inside the myocytes FABP may be involved in the transport of fatty acids from the
sarcolemma to the sites of conversion i.e. mitochondrial and sarcoplasmic reticulum
(Fournier and Rahim 1985, Glatz and Yeerkamp 1985). TAG must be hydrolysed to
NEFA and mono- and/or diacylglycerol by lipoprotein lipase on the luminal side of the
endothelium before the fatty acids can pass the endothelial barrier (Stam and Hulsmann
1985).
After being taken up by the myocardium, the first step in NEFA oxidation is the
energy-dependent activation of NEFA to form acyl CoA. When the circulating NEFA
concentrations are high, and NEFA extraction by the heart is also elevated, the rate of
NEFA activation will also rise. However, as more acyl CoA is formed, the cytosolic free
CoA concentration decreases, and activation of NEFA therefore slows down.
Conversely, during increased heart work the rate of mitochondrial oxidation rises, tissue
acyl CoA concentrations fall and NEFA activation is stimulated (Opie 1984).
Increased oxidation of NEFA results in a decrease in the rate of glycolysis due to
increased ATP, NAD and citrate concentrations and therefore inhibition of the regulatory
enzymes of glycolysis (Opie 1968, Neely and Morgan 1974).
The transport of long chain acyl CoA into the mitochondria is achieved by a shuttle
mechanism in which acyl-carnitine, formed by the action of carnitine acyl transferasel,
which can cross the mitochondrial membrane, is the intermediate. Carnitine-
acylcamitine translocase acts as a membrane carnitine exchange transporter.
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Acylcarnitine is transported into the mitochondria, coupled with the transport out of one
molecule of carnitine. Acylcarnititne then reacts with acyl CoA, catalyzed by carnitine
acyltrasferase II which is attatched to the inside of the inner mitochondrial membrane.
Acyl CoA is reformed in the mitochondrial matrix, with the subsequent liberation of
carnitine. The stepwise degradation of acyl CoA to acetyl CoA via P-oxidation yields
reduced flavoprotein and NADH. Acetyl CoA is further degraded by the enzymes of the
Krebs cycle, also located in the mitochondrial matrix, leading to further formation of
reduced coenzymes and 1 molecule of GTP. The reduced coenzymes are oxidized in the
electron transfer chain with the concomitant formation of ATP. Alternatively, activated
NEFA which is not oxidized may be ultimately stored as TAG or transferred to structural
lipids.
1.2.4. Triacylglycerol (TAG) metabolism.
TAG is stored in lysosomes and as lipid droplets in the sarcoplasm (Hulsmann and
Stam 1979, Stam et al. 1980).
TAG is synthesized in the heart from acyl CoA and a-glycerophosphate, the latter
being derived from glycolysis or direct phosphorylation of glycerol by the action of
glycerokinase. However, the activity of this enzyme is generally assumed to be negligible
in the heart (Challoner and Steinberg 1965, Christian et al. 1968, Jesmok et al. 1977,
Trach et al. 1984, Stam and Hulsmann 1981a).
The free hydroxy groups of a-glycerophosphate are acylated with fatty acyl CoA by
the action of glycerophosphate acyltransferase to form phosphatide acid, an important
intermediate in the synthesis of both TAG and phospholipids (phospholipid synthesis
beyond the scope of this brief overview). Subsequent hydrolysis of the phosphate group
at the 3 position by phosphatidate phosphatase yields diacylglycerol. The third free
hydroxyl group then reacts with acyl CoA to form TAG. The release of fatty acids
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stored in TAG is accelerated by the action of TAG lipases. As with glycogen, TAG
stores are continually turning over. Separate pools of TAG with different turnover rates
may exist in the heart (Stein and Stein 1968, De Groot et al. 1989). The regulation of
TAG metabolism will be discussed in detail later (Section 1.4.2.).
1.2.5. High energy phosphate production and utilization.
Hydrolysis of ATP is the immediate source of energy for contraction, maintenance of
ion gradients and other vital cellular functions. There is a delicate balance between
synthesis and degradation of ATP.
Acetyl CoA entering the citric acid cycle produces NADH + H+. Hydrogen atoms
flow along the electron transfer chain where ADP is converted to ATP during oxidative
phosphorylation. Once formed in the mitochondria, ATP is transported to the cytosol
via an ATP translocase with counter exchange of ADP into the mitochondria. On
entering the cytoplasm ATP may be utilized, resulting in ADP formation. The rates of
synthesis and breakdown of ATP are therefore closely linked.
The rate at which the citric acid cycle operates is a major factor controlling the rate of
production of ATP by the heart, because this cycle regulates the formation of NADH +
H+. Two dehydrogenases of the cycle, isocitrate dehydrogenaase and a- ketoglutarate
dehydrogenase are sensitive to calcium. a-Ketoglutarate dehydrogenase is also inhibited
by succinyl CoA (Garland 1964). Pyruvate dehydrogenase is also activated by calcium
ions (Denton and McCormack 1980, Coll et al. 1982).
Oxidation of NADH is coupled to phosphorylation of ADP in the mitochondria in such
a way that 3 molecules of ATP are formed for each atom of oxygen utilized (P/O ratio of
3). Depending on the substrate oxidized, the exact P/O rates will vary from 2.85 to 3.15.
The variations in the P/O ratio reflect the number of oxygen atoms of the substrates.
Thus, glucose, already containing some oxygen atoms in its structure needs addition of
16
less oxygen added to produce H2O than does fatty acid.
Another important energy store in the heart is creatine phosphate (CP). This may act
as a buffer store of high energy phosphate for ATP. A phosphate group may be
transferred from creatine phosphate to ADP by the action of creatine kinase, resulting in
formation of ATP. The equilibrium of this reaction favours formation of ATP by about
50 times (Opie 1984).
CP may also act as a shuttle in transporting high energy phosphate from the
mitochondria to its site of utilization. Creatine phosphokinase converts newly
synthesized ATP to CP in the mitochondria, liberating ADP which can be shuttled back
to the mitochondroial matrix. CP then travels into the cytosol and is converted to ATP
by creatine phosphokinase at or near the sites of ATP hydrolysis such as the contractile
proteins and sarcolemma.
The concentration of CP in the heart is normally around 10 pmoles per gram wet
weight. This is equivalent to twice the normal myocardial ATP concentration.
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1.3. Comparison of hypoxia and ischaemia.
Hypoxia has been defined as a supply of oxygen insufficient to meet the oxygen
requirements of the tissue whereas ischaemia is an imbalance between the supply of
oxygenated blood and the oxygen requirements of the myocardium. The major
difference between hypoxia and ischaemia is that coronary flow rate increases during
hypoxia (although in some experimental models it may be controlled using a pump)
whereas by definition ischaemia entails a decrease in flow rate.
Hypoxia may range from mild to severe. Complete lack of oxygen is termed anoxia.
Complete abolition of blood flow to the myocardium is termed "global ischaemia".
When ischaemia is confined to a region of the heart, but doesn't affect the whole heart,
the term "regional ischaemia" is used. Many arrhythmias occur due to the onset of acute
myocardial (regional) ischaemia (Reimer and Jennings 1986). Hypoxia is an important,
perhaps the most important component of ischaemia.
Ischaemia results in a decreased supply of oxygen and nutrients to the tissue, and also
decreased removal of waste products of metabolism. The distinction in myocardial
metabolism between ischaemia and hypoxia is most dramatically demonstrated by
contrasting the potential for energy production via anaerobic glycolysis in ischaemia and
hypoxia (Neely et al. 1973). During ischaemia, glycolysis is initially stimulated due to
the decreased energy status of the cell. However, the lactate concentration in the tissue
rapidly increases and tissue acidosis ensues. This is accompanied by a marked slowing
of anaerobic glycolysis (Jennings et al. 1981, Rovetto et al. 1973). Although glucose
extraction is stimulated during ischaemia, glucose uptake is also governed by flow, and is
thus limited.
The mechanism for the slowing of glycolysis is thought to be inhibition of
glyceraldehyde-3-phosphate dehydrogenase by lactate and NADH and may also be due to
inhibition of phosphofructokinase by lactate and hydrogen ions, and the declining
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availability of pyruvate (Neely and Morgan 1974, Rovetto et al. 1975).
In contrast, during hypoxia, lactate accumulation and cellular acidosis are prevented by
the maintained flow rate. Anaerobic glycolysis therefore proceeds at an accelerated rate
so long as substrates remain available (Neely et al. 1975).
The effect of normoxia, hypoxia and ischaemia on glycolysis are shown in Figure 1.3.
The major differences between hypoxia and ischaemia are shown in Table 1.1.
Table 1.1.
HYPOXIA ISCHAEMIA
Flow rate t I
Oxygen supply \ \
Exogenous substrate supply f |
Removal of waste products t I
\ = Decrease t = Increase
In models of hypoxia in which coronary flow rate is contolled by means of a pump,
substrate supply and removal of waste products are unchanged.
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Hypoxia is often used as an experimental model of myocardial ischaemia (section 1.6.).
The following section gives a brief overview of the biochemical changes in the heart
during hypoxia. Some aspects of metabolism have been studied in models of ischaemia
only, and no data is available for the hypoxic heart. Although the effects of ischaemia
cannot be directly extrapolated to hypoxia, the metabolic changes during early ischaemia
are similar to those seen during hypoxia.
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1.4 Metabolism of the heart during hypoxia.
At the onset of hypoxia, coronary flow is increased to compensate for the decreased
oxygen supply to the tissue.
When oxygenation of the myocardium is compromised, the function of the electron
transfer chain becomes limited due to the absence of oxygen as the ultimate acceptor of
electrons. Electron transport is retarded, and formation of ATP by oxidative
phosphorylation is inhibited (Scheuer 1967).
Reduced flavin and nicotinamide co-enzymes are not oxidized and hence accumulate in
the mitochondria. The ensuing decrease in availability of NAD+ leads to inhibition of
key enzymes in the citric acid cycle (isocitrate dehydrogenase and a-ketoglutarate
dehydrogenase) which require NAD+ as a cofactor. Conversion of pyruvate to acetyl
CoA also requires NAD+ as a cosubstrate and is therefore inhibited when the oxygen
supply is decreased. The pyruvate dehydrogenase complex is also inhibited via covalent
modification by a cAMP-dependent protein kinase. Entry of acetyl CoA into the citric
acid cycle is thus reduced. The regulatory enzymes of glycolysis are also affected. The
relevant aspects of myocardial metabolism during hypoxia are discussed in the following
section.
1.4.1. High energy phosphate production and utilization during hypoxia.
Myocardial ATP levels result from production and utilization buffered by a store of CP.
As oxidative phosphorylation is inhibited during oxygen deprivation, the heart must rely
on anaerobic glycolysis for ATP production. This process can only partly substitute for
aerobic ATP generation. ATP is broken down to ADP and AMP and these metabolites
increase in concentration when the oxygen supply is low. Enough ATP may be
produced anaerobically to maintain some contractile function during hypoxia, providing
that there is adequate substrate supply (Weissler et al. 1968). The high energy
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phosphate stores in the heart could only support normal contractile activity for a few
seconds without replenishment (Opie 1984). Decreased availability of oxygen is partly
compensated for by increased coronary flow rate. Nevertheless, even under conditions
of maximum stimulation, anaerobic glycolysis can produce no more than about 7% of the
high energy phosphate needs of the working myocardium (Kobayashi and Neely 1979).
Creatine phosphate (CP) in the heart is continually turned over to form creatine, with
the accompanying formation of ATP from ADP. When ATP formation is inhibited,
ADP and AMP concentrations increase. ATP concentrations during hypoxia are initially
maintained at the expense of CP. ATP is used directly in muscular contraction, causing
isolated actomyosin threads to shorten (Opie 1984). It is logical that the concentration
of ATP in the myocytes should be maintained at the expense of CP, with the CP pool
suffering from more marked depletion than ATP. Hence, a small early fall of ATP
precedes a large fall in CP (Feinstein 1962, Neely et al. 1973, Hearse 1979).
The rate of utilization of high energy phosphates is rapidly reduced during hypoxia
because contractile function is suppressed. Nevertheless, electrical activity and minimal
mechanical activity continue to utilize high energy phosphates; other reactions utilizing
ATP include those involved in calcium sequestration by the sarcoplasmic reticulum, the
sarcolemmal Na+-K+ ATP ase and adenylate cyclase.
Compartmentalization of ATP between the mitochondria and the cytoplasm is well
accepted. Subcompartments of ATP may also exist within the cytoplasm. It has been
suggested that specific pools of ATP are used for contraction (Opie 1983). Decreased
ATP and CP, and increased ADP concentrations are observed within 2 minutes of the
onset of global ischaemia in the isolated, perfused rat heart. After 20 minutes, a further
decrease in ATP concentration can be seen and ADP concentration returns to normal.
At this point, AMP levels have increased five-fold. The effects of duration or severity
of hypoxia rather than ischaemia on myocardial metabolism have not been studied.
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1.4.2. Glucose metabolism during hypoxia.
Glucose uptake by the heart is stimulated during hypoxia (Morgan et al 1961).
Phosphofructokinase activity is also stimulated due to the increase in AMP concentration
and concomitant decrease in ATP concentration in the tissue. In addition, the increased
NADH/NAD+ ratio inhibits glyceraldehyde-3-phosphate dehydrogenase activity and
therefore reduces pyruvate formation. Glyceraldehyde- 3-phosphate dehydrogenase is
also inhibited by decreased pH in the tissue (Rovetto et al. 1975), which is a consequence
of hypoxia due to increased lactate production. Entry of pyruvate into the citric acid
cycle is inhibited (Lemley and Meneely 1952) and conversion of pyruvate to lactate is
stimulated by the increased NADH/NAD+ ratio. Lactate formation serves to remove
NADH and provide NAD+ to maintain anaerobic glycolysis (Krasnow et al. 1962). In
addition, the increased NADH/NAD+ ratio favours formation of a- glycerophosphate
from dihydroxyacetone phosphate (DHAP), therefore providing a precursor for TAG
synthesis.
The rate of anaerobic glycolysis is therefore stimulated during hypoxia but inhibition
of oxidative metabolism results in increased lactate production and decreased oxidation
of glucose.
1.4.3. Glycogen metabolism during hypoxia.
During the first few seconds of hypoxia, glycogen phosphorylase activity is the rate
limiting step for anaerobic energy production (Kubler and Spieckermann 1970).
However, there is a rapid increase in phosphorylase activity during the first 10 sec of
ischaemia which is due to
a) Activation of phosphorylase b by increased AMP and inorganic phosphate
concentrations.
b) Decreased inhibition of phosphorylase a because of decreased ATP and glucose-6-
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phosphate concentrations (Opie 1976).
c) conversion of phosphoylase b to phosphorylase a (Dobson and Mayer 1973, Kubler
and Spieckermann 1970). This is achieved through B-adrenergic stimulation of
adenylate cyclase, resulting in cAMP production (Hough and Gevers 1975).
Glycogen synthetase activity may also increase due to cAMP-mediated activation of
the kinase which activates glycogen synthetase (Huijing and Larner 1966). Thus at the
onset of hypoxia or ischaemia both glycogen synthesis and degradation may be activated
(Williams and Mayer 1966, Opie 1970). As the duration of oxygen depletion increases,
glycogen synthesis is limited by availability of high energy phosphates. Thus there is a
shift towards increased glycogen degradation.
It has been suggested that myocardial glycogen stores may play an important role in the
protection of the myocardium against arrhythmias (Russell et al. 1986). However, this
function of glycogen is controversial and not well understood.
1.4.4. Fatty acid metabolism during hypoxia.
Oxidation of fatty acids is inhibited during hypoxia. It has been suggested that
intermediates of fatty acid metabolism such as acyl CoA and acyl carnitine may
accumulate in the tissue during oxygen deprivation and have deleterious effects on
cellular function although this has only been demonstrated during ischaemia (Kurien and
Oliver 1970, Opie 1970, Liedtke et al. 1978, Shug et al. 1978).
Studies looking at changes in NEFA have been hampered by technical difficulties in
the measurement of tissue NEFA levels. Overestimation of NEFA concentrations has
been attributed to methodological artefacts such as hydrolysis of tissue derived lipids
during extraction and separation of lipids (Van der Vusse and Reneman 1984, Van der
Vusse et al. 1985). The NEFA content of the heart represents less than 1% of the total
amount of fatty acids (Van Bilsen et al. 1989). Hydrolysis of a small amount of either
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phospholipds or TAG could thus lead to a large difference in NEFA levels.
In vivo, tissue NEFA concentrations may be raised during hypoxia or ischaemia
because of increased extraction of NEFA from the plasma due to increased plama levels
(Riemersma 1979, Vik-Mo et al. 1979) and increased myocardial lipolysis. However,
re-esterification of NEFA is also stimulated during hypoxia, removing some of the
excess NEFA (Scheuer and Brachfield 1966, Jesmok et al. 1978, Shug et al. 1978).
Increased concentrations of arachidonic acid have been demonstrated in ischaemic
myocardium in the early phase of injury (Chien et al. 1984, Prinzen et al. 1984). This
fatty acid is a major component of phospholipids and its presence is thought to provide
evidence for degradation of phospholipids. The tissue concentration of
lysophospholipids also increases during ischaemia (Sobel et al. 1978, Corr et al. 1982).
However, accumulation of lysophospholipids on a quantitative basis appears to be of
minor importance (Shaikh and Downar 1981, Chien et al. 1984, Van Bilsen 1988) and
becomes substantial only in necrotizing tissue after prolonged ischaemia (Steenbergen
and Jennings 1984).
Elevated cellular NEFA concentrations may have deleterious effects on several cellular
processes in vitro. These include effects on glycolytic enzymes (Lea and Weber 1968,
Ramadoss et al. 1978), reduced activity of the sarcolemmal bound Na+/K+ ATPase
(Lamers and Hulsmann 1977) and disturbance of calcium homeostasis (Katz et al. 1979).
However, accumulation of NEFA does not occur until one hour after the onset of
ischaemia and infusion of NEFA into the blood during acute ischaemia failed to cause
serious ventricular arrhythmias. NEFA accumulation is therefore an unlikely cause of
arrhythmias during early ischaemia (Van der Vusse et al. 1987).
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1.4.5.TriacylgIycerol metabolism during hypoxia
Myocardial lipolysis, mediated via a catecholamine-dependent mechanism is
thought to be stimulated during oxygen deprivation (Crass and Pieper 1975, Christian et
al. 1968, Jesmok et al. 1977). Anoxia-stimulated lipolysis, demonstrated by increased
glycerol release, could not be shown in hearts from rats depleted of endogenous
catecholamines by pretreatment with reserpine (Karwatowska-Krynska and Beresewicz
1983). However, re-esterification is also stimulated during hypoxia and this is facilitated
by increased a-glycerophosphate production due to increased glycolytic flux. Several
investigators have reported an increase in the myocardial content of TAG in flow
deprived tissues (Jesmok et al. 1978, Burton et al. 1986).
The onset of hypoxia evidently involves a complex and interacting series of
biochemical changes. The changes during the first few minutes after the onset of
hypoxia are compensatory and there is an increase in glycolytically produced ATP. This
may minimize tissue damage. However, if hypoxia is prolonged, depletion of energy
supplies may be so severe as to irreversibly damage myocardial function. This is
demonstrated by amorphous matrix densities in the mitochondria and tiny breaks in the
plasmalemma of the sarcolemma (Jennings and Reimer 1981, Reimer et al. 1983).
Release and activation of lysosomal phospholipases or proteases is also apparent (Decker
and Wildenthal 1978, Wattiaux and Wattiaux-De Connick 1984, Welman 1974).
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1.5. Regulation of lipolysis in the heart.
Although the process of endogenous lipolysis in the heart is a well known
phenomenon, there is no consensus of opinion with regard to the mechanisms involved.
The nature and localization of the metabolically active TAG pool (or pools) is unclear,
and the enzymes involved in myocardial lipolysis under various conditions are unknown.
A summary of present knowledge of the control of lipolysis is given in the following
sections.
1.5.1. Hormone-stimulation of lipolysis.
Each mole of TAG hydrolyzed in the heart gives rise to 3 moles of NEFA and 1 mole
of glycerol. As glycerol is readily released into the coronary effluent, and myocardial
glycerokinase activity is thought to be negligible, glycerol release has been well accepted
as an index of TAG breakdown (Christian et al. 1968, Brownsey and Brunt 1977, Trach
et al. 1984, De Groot et al. 1989). Catecholamines are well known to stimulate TAG
hydrolysis in the heart as demonstrated both by increased rates of glycerol output
(Williamson 1964, Challoner and Steinberg 1965, Christian et al. 1968, Brownsey and
Brunt 1977, Hulsmann and Stam 1978) and decreased levels of TAG (Gartner and
Vahoury 1973, Crass et al. 1975). In addition dibutyryl cAMP and theophylline have
been shown to stimulate TAG breakdown (Crass et al. 1975).
Hormone-stimulated lipolysis in the heart is achieved via a (3.-receptor, cAMP, protein
kinase mediated cascade (Christian et al. 1968; Fig 1.4).
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Isoprenaline-stimulated glycerol release may be blocked by the ^-adrenoceptor
antagonist propranolol, and a rise in cAMP levels was observed before the increase in
glycerol release in isolated hearts perfused in the presence of the catecholamine analogue
isoprenaline (Christian et al. 1968). In addition, increased glycerol release from hearts
perfused with catecholamines was associated with an increased protein kinase activity
ratio (Jesmok et al. 1977, Hron et al. 1976). This was shown to be dependent on a Ca++
concentration greater than 1.2mM (Hron et al. 1976). A protein kinase inhibitor was
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found to block activation of a myocardial TAG lipase (Palmer et al. 1987). Also,
blockade of noradrenaline reuptake in isolated perfused rat hearts by phenoxybenzamine
increased TAG lipase activity (Hough and Gevers 1975), and depletion of endogenous
catecholamines by pretreatment with reserpine resulted in inhibition of ischaemia
induced increases in TAG lipase activity (Hough aand Gevers 1975) and hypoxia-
stimulated glycerol release (Karatowska-Krynska and Beresewicz 1983).
The effects of a-adrenoceptor stimulation on myocardial lipolysis are not as well
documented as P-adrenoceptor effects, ocj-adrenoceptor stimulation is thought to inhibit
lipolysis whereas a,-adrenoceptor stimulation results in the breakdown of
phosphatidylinositol to form IP3 which stimulates release of Ca++ from the sarcoplasmic
reticulum, and diacylglycerol which activates protein kinase C. The effects of increased
intracellular Ca++ concentrations and protein kinase C activation on lipolysis in the heart
do not appear to have been studied.
Holm et al. (1988) used an antibody raised against purified adipose tissue hormone-
sensitive lipase to detect the enzyme in rat heart tissue. Hormone-sensitive lipase was
partially purified from heart muscle and was found to be phosphorylated by cyclic AMP-
dependent protein kinase. Phosphorylation of the purified enzyme resulted in increased
enzyme activity (Small et al. 1989). Holm et al. (1988) determined the sequence of
adipose tissue hormone sensitive lipase using cloned rat adipocyte complementary DNA.
Messenger RNA species for the protein were found to be expressed in heart tissue.
1.5.2. Regulation of lipolysis by product inhibition.
Under normoxic conditions myocardial lipolysis in the isolated, perused rat heart was
subject to product inhibition by increased exogenous concentrations of NEFA (0.25 mM
to 0.6 mM; Crass III et al. 1975, Hron et al. 1978, Stam and Hulsmann 1981, Severson
and Hurley 1982). Cardiac lipase activity in rat heart homogenates was inhibited in the
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presence of palmitoyl CoA (lOOuM) and stimulated in the presence of albumin (3%).
This was suggested to be via removal of NEFA (McDonough and Neely 1988).
However, palmitoyl CoA is well known to possess detergent-like properties at
concentrations much lower than 100 (iM and its effects at this concentration are therefore
likely to be non specific.
1.5.3. The role of a-glycerophosphate in the control of lipolysis.
The supply of a-glycerophosphate for TAG synthesis may also be an important factor
in the control of lipolysis. This may be due to removal of product inhibition as a
consequence of enhanced NEFA re-esterification (Schoonderwoerd et al. 1989).
However, glycerol release from isolated, perfused rat hearts was increased in the
presence of lactate (De Groot et al. 1989). This was attributed to stimulation of TAG
turnover due to an increase in the NADH/NAD+ ratio and hence increased a-
glycerophosphate production. The increased lipolysis in hearts perfused in the presence
of lactate was accompanied by raised tisue NEFA levels compared with control hearts,
ruling out the possibility that lipolysis was stimulated due to removal of product
inhibition. Part of the myocardial TAG pool may have been converted into a separate
pool which was more readily accessible to TAG lipase. TAG pools with different
turnover rates have previously been reported (Stein and Stein 1968, Olson and Hoeschen
1967). The importance of a-glycerophosphate production for TAG synthesis in rat heart
homogenates has been demonstrated (Wood et al. 1972). cAMP protein-kinase
stimulation of TAG lipase activity in rat heart homogenates was dependent on the
presence of glycogen, probably for a-glycerophosphate production (Schoonderwoerd et
al. 1987). The involvement of a-glycerophosphate in TAG metabolism is illustrated in
Fig 1.5.
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1.5.4. Other factors involved in the regulation of lipolysis.
Paracrine effects may also be present in the heart. Prostaglandins may influence
lipolysis. Prostaglandin Ej is known to be an inhibitor and the effects on myocardial
lipolysis are dose-dependent (Riemersma 1979). Thromboxane and prostacyclin may be
released from endothelial cells and subsequently influence metabolism of the myocytes.
The influence of these substances on TAG metabolism in the heart does not appear to
have been studied. Adenosine production in the heart results in inhibition of adenyl
cyclase and thus decreased cAMP production and inhibition of hormone-stimulated
lipolysis.
1.5.5. TAG lipases of the myocardium.
Several TAG lipases have been described in heart muscle.
a) Lipoprotein lipase - this enzyme is bound to the capillary endothelium and functions in
the uptake of tissue NEFA by hydrolysis of the TAG component of circulating
lipoproteins (Brockerhoff and Jensen 1974, Robinson 1970). Lipoprotein lipase may be
released from its tissue sites by heparin. The enzyme has an alkaline pH optimum (8-
8.5) and is inhibited by protamine sulphate and high NaCl concentrations (Twu et al
1975).
b) Neutral lipase - This enzyme has a pH optimum of 7.5 to 8.
c) Acid lipase - This enzyme is thought to originate from lysosomes (Wang et al. 1977,
Hulsmann and Stam 1979) and has an acid pH optimum (4.5 to 5) (Severson 1979).
Besides TAG lipase activity, both microsomal DAG hydrolase and MAG hydrolase
enzymes have been characterized (Stam et al. 1986). The activity of both these enzymes
far exceeds that of TAG lipase, hence the latter enzyme is more important in the
regulation of lipolysis.
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1.5.6. Involvement of TAG lipases in hormone-stimulated lipolysis.
The identity of the lipase responsible for hormone-stimulated lipolysis in the heart has
been controversial. Different studies have cited neutral lipase or lysosomal lipase as
being responsible for basal and hormone-stimulated lipolysis in the heart.
Noradrenaline-stimulated lipolysis, demonstrated by glycerol release from the isolated,
perfused rat heart was inhibited by the lysosomotropic agent chloroquine (Hulsmann and
Stam 1978, Hulsmann et al. 1979), and lysosomal TAG levels decreased during
perfusion (Stam et al. 1986). However, this decline represented only a small fraction
(10%) of the total fall in TAG measured. Basal and glucagon-stimulated glycerol
release were unaffected in isolated, perfused hearts from rats pretreated with
cyclohexamide to deplete neutral TAG lipase activity (Stam et al. 1986). In addition,
uptake and degradation of TAG by isolated lysosomes has been demonstrated
(Schoonderwoerd et al. 1990). The lysosomotropic agent methylamine inhibited
ischaemia-stimulated glycerol release in the isolated, perfused rat heart (Schoondewoerd
et al. 1990). However, this was in the presence of a relatively low Ca++ concentration
(1.3mM) at which lipolysis has been shown to be inhibited (Hron et al. 1977). The
effect of the drug was not examined in the presence of higher Ca++ concentrations.
Lysosomotropic agents were unable to inhibit basal or hormone stimulated glycerol
release in isolated myocytes (Kryski et al. 1987) or the isolated, perfused rat heart
(Severson et al. 1980, Rosen et al. 1981). Aupecle and Pinson (1982) suggested that
lysosomal lipases may hydrolyse TAG only under conditions of lipid accumulation.
However, even in myocytes isolated from diabetic rats in which TAG concentrations are
raised, the lysosomotropic agent methylamine had no effect (Kryski et al. 1987). The
reasons for the discrepancies between studies using lysosomotropic agents are not
apparent, and other, possibly non-specific effects of the drugs should be taken into
consideration. For example, chloroquine is an inhibitor of phospolipase A2 (Harris et al.
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1988, Fazekas and Szekeres 1988).
The hormone-sensitive lipase purified from heart tissue by Small et al. (1989) had a
neutral pH optimum. This enzyme exhibited identical properties to the hormone-
sensitive lipase of adipose tissue. Furthermore, the enzyme was present in isolated
myocytes, excluding the possibility that the lipase activity was derived from
intramuscular adipocytes or other cell types. However, a lack of hormone- sensitivity of
the neutral TAG lipase has been reported (Kawamura et al. 1981, Rosen et al. 1981, Stam
and Hulsmann 1985).
More work is obviously needed to elucidate the key enzymes, and the mechanisms
involved in the regulation of lipolysis.
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1.6. The isolated Langendorff perfused hypoxic rat heart as an experimental model.
The rat is a useful animal model due to its small size, relatively low cost and
availability. As it is commonly used as a model, results may be easily compared with
those of other workers.
The isolated, perfused hypoxic rat heart provides a useful model for quantitative
biochemical studies (De Leiris et al. 1984). The heart is isolated from the rest of the
body and so is free of complicating factors such as hormonal and neural influences and
cellular blood elements which may affect metabolism in vivo.
The acute consequences of hypoxia can be studied more easily in the isolated heart
model. Both arterial and venous perfusate samples are readily accessible, allowing
monitoring of substrate utilization and metabolite production. At any time necessary the
heart may be freeze clamped, and concentrations of metabolites in the tissue measured.
Non-invasive techniques such as nuclear magnetic resonance (NMR) may also be used to
monitor the biochemical changes in the heart throughout an experiment. In addition,
drugs may be easily infused into the heart during perfusion.
Hypoxia has some advantages over the regional ischaemic heart model for use in
quantitative metabolic studies. When coronary effluent is collected from a regionally
ischaemic heart, the sample consists of a mixture of perfusate from the normoxic tissue
and perfusate from the ischaemic area and the relative amounts of these cannot easily be
assessed. Also, the heart tissue is a mixture of normal and ischaemic myocardium.
Although the normal and ischaemic tissue may be separated, this is technically difficult,
particularly after freeze-clamping the tissue. The ischaemic area itself is not
homogeneous. The main advantages of the use of ischaemia is that this model is closer to
the situation in the human heart during acute myocardial infarction, and that arrhythmias
may be monitored whereas arrhythmias do not occur during hypoxia.
Global low-flow ischaemia may be used. However, in this situation only small
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volumes of coronary effluent may be collected, and maintenance of tissue temperature is
difficult at low flow rates.
The isolated, perfused heart is a heterogeneous tissue and in addition to myocytes
consists of other cell types such as endothelial cells, connective tissue and adipocytes.
The contribution of the metabolism other cell types to the metabolism of the heart as a
whole is not always clear. This may be a problem in measuring release of metabolites
and hormones such as prostacyclin.
In most isolated heart models the perfusate does not contain haemoglobin as a means of
oxygen transport. This requires that flow rates much higher than those in vivo are
required, and perfusate of high oxygen tension must be used to maintain adequate
oxygenation of the tissue. The use of high flow rates without replacing colloid content
runs the risk of development of intersitial myocardial oedema.
Isolated myocytes may also be used as a model of hypoxia. The contribution of other
cells is therefore removed, and diffusion of extracellular molecules such as oxygen is
more efficient in isolated cells, removing the problem of unphysiological flow rates.
However, isolation of the cells per se may change their properties. Separation of cells
requires treatment with collagenase or hyaluronidase which may in itself affect cellular
function. In addition, myocytes must be separated from each other at the intercalated
discs (Yokoyama et al. 1961). This is usually accomplished by brief exposure to a
calcium-free solution, which runs the risk of cells becoming calcium intolerant
(Zimmerman et al. 1967, Ganote et al. 1981).
Obviously all experimental models have advantages and disadvantages. On the whole,
the advantages of the hypoxic isolated, Langendorff perfused rat heart outweigh the
disadvantages and it provides a useful model for the study of myocardial metabolism
without the complicating factors which are present in vivo.
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1.7. Myocardial lipid metabolism and arrhythmogenesis
The clinical observation that in patients admitted to hospital with acute myocardial
infarction, incidental measurements of plasma NEFA concentrations are raised was made
by Oliver et al. (1968). The rise in plasma NEFA concentrations during acute
myocardial infarction has been attributed to increased sympathetic nervous system
activity (Vetter et al. 1974, Christensen and Vidabaeck 1974), stimulating lipolysis in
adipose tissue. The increased noradrenaline secretion in dogs after coronary artery
ligation was linked with, and put forward as, a possible cause of arrhythmias
(Ceremuzynski et al. 1969).
In an alternative hypothesis, Kurien and Oliver (1970) suggested that acute lipid
mobilization from adipose tissue may lead to accumulation of 'unbound' NEFA within
the ischaemic myocardium where they may exert detergent effects on cell membranes
causing cation loss and hence induce arrhythmias. Therefore, rather than being a
"harmless" biochemical reflection of increased sympathetic nervous system activity,
NEFA were thought to have a fundamental role in the genesis of arrhythmias.
In support of this hypothesis, the incidence of arrhythmias during the early phase of
acute myocardial infarction could be reduced by antilipolytic therapy independent of
changes in plasma catecholamine concentrations (Rowe et al. 1975). Increased NEFA
uptake by the heart in open-chest anaesthetized dogs could increase myocardial oxygen
consumption, irrespective of effects on mechanical activity (Mjos 1971). In addition,
inhibition of lipolysis by both antilipolytic agents and by increasing blood glucose levels
was found to attenuate the increase in myocardial oxygen consumption induced by
isoprenaline (Mjos 1976). Furthermore, inhibition of lipolysis by the nicotinic acid
analaogue (3-pyridyl carbinol could prevent the increased S-T segment elevation caused
by coronary occlusion in anaesthetized dogs (Kjekshus and Mjos 1973).
However,in subsequent studies using a similar model, infusion of NEFA salts bound to
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albumin into the blood failed to precipitate ventricular fibrillation (Riemersma 1979).
This led to the suggestion that a TAG-NEFA "wasteful" cycle may operate in the
ischaemic myocardium (Fig 1.6), and could be a stimulus for arrhythmias (Riemersma
1987). During early ischaemia, myocardial lipolysis is activated (Brownsey and Brunt
1977, Hough and Gevers 1975, Jesmok et al. 1978, Vik-Mo et al. 1979). |3-oxidation is
inhibited and NEFA re-esterification increases (Jesmok et al. 1978, Scheuer and
Brachfield 1966, Shug et al. 1978). The operation of the cycle during acute myocardial
ischaemia is therefore very likely. The TAG-NEFA cycle would be energy-requiring
and may therefore be detrimental to the myocardium in consuming ATP supplies for the
energy-dependent ion pumps. This may disturb membrane potentials and hence cause
arrhythmias. If the rate limiting step of the cycle was lipolysis, infusion of NEFA may
inhibit the cycle by exerting product inhibition on myocardial lipolysis, explaining the
failure of infusion of NEFA to precipitate arrhythmias (Riemersma 1987).
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1.8. The TAG-NEFA cycle.
The operation of a TAG-NEFA cycle in adipose tissue is well established (Newsholme
and Start 1974). The cycle is thought to be a means of improving the sensitivity of
metabolic and endocrine control (Newsholme et al. 1984). It may also play a role in
heat production during dietary-induced thermogenesis (White et al. 1984). The cycle
has been shown to be sensitive to specific hormones. The cycling rate in adipose tissue
was increased markedly by P-adrenergic agonists, and the effect was abolished by the P-
blocker propranolol (Brooks et al. 1982). In addition, the rate of the TAG-NEFA cycle
in adipose tissue in vivo was doubled by feeding (Brooks et al. 1983) and markedly
increased by glucagon, ACTH and TSH (Brooks et al. 1982). There is strong evidence
for the existence of a TAG-NEFA cycle in heart muscle during ischaemia or hypoxia
(Vik-Mo and Mjos 1981, Vik-Mo 1983, Riemersma 1987). The use of in vivo models in
these studies prevented quantification of ATP wastage and rates of TAG-NEFA cycling.
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HYPOTHESIS.
A TAG-NEFA "wasteful" cycle operates in the heart during
oxygen deprivation. This leads to depletion of myocardial ATP
supplies for the energy-dependent ion pumps, disturbance of






2.1.1. Animal Housing Conditions
Rats were housed at constant temperature (21±1°C), with a cycle of 12 h dark, 12 h
artificial light. Free access to food (commercial laboratory chow; Bantin and Kingman)
and water was given unless stated otherwise.
2.1.2. Langendorff perfusion
Rats were anaesthetised using an intraperitoneal injection of sodium pentabarbitone (60
pg/g body weight). Heparin (0.25 units/g body weight) was injected via the femoral
vein a minimum of 30 s prior to removing the heart to ensure adequate distribution
throughout the blood pool. After abdominal section the chest cavity was opened by
cutting through the diaphragm and ribs. The heart and lungs were rapidly excised and
immediately placed in ice cold perfusate.

















Bulk lung tissue was carefully removed and when no further contractions occurred, the
heart was mounted on a perfusion cannula and secured using a 2/0 Mersilk thread.
Hearts were perfused retrogradely, according to the Langendorff technique using a non-
recirculating, double reservoir system (Fig 2.1). The perfusate was a modified Ringer
Locke solution (Table 2.1), containing glucose (5.5 mM). This solution was freshly
prepared using double distilled water before every experiment. The temperature was
maintained at 37°C. The flow rate, controlled by a Harvard peristaltic pump was 10
ml/min. After a stabilization period of 20 min, the pulmonary artery was cannulated
using Portex nonsterile polyethylene tubing (I.D. 0.86 mm) to enable anaerobic sampling
of coronary effluent for calculation of myocardial oxygen uptake. Hearts were perfused
for 30 min using 95%02 /5%CC>2 followed by a further 30 min perfusion as specified in
the text for each experiment.
Samples were collected from the gassed perfusate in the reservoir, and the pulmonary
artery. pH, pC>2 , and pCC>2 were measured using an Instrumentation Laboratories
SYSTEM 1302 pH/Blood Gas Analyser. Throughout the perfusion period coronary
effluent was collected at 5 or 10 min intervals. Samples were analyzed for glycerol and
lactate either within lh of collection or after storage at -40°C . At the end of the
perfusion period, the hearts were rapidly cooled to the temperature of liquid nitrogen
using a Wollenberger clamp, and then freeze dried for 48 hours (room temperature) using
an Edwards Modulyo freeze drier.
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2.1.3. Homogenization and extraction of metabolites
After freeze drying for 48 h, each heart was weighed. The atria and ventricles were
separated and the ventricles pulverized using a B.Braun Mikro- dismembrator II (McKay
and Lynn, Edinburgh).
Approximately 50 mg of powdered heart tissue was weighed and the exact weight
noted. This tissue was then placed in a 5 ml plastic tube and 3 ml 0.6M perchloric acid
was added.
The remainder of the powdered heart tissue was then weighed and stored at -40°C
before being analyzed for triacylglycerol.
Homogenate (200 |il) was removed, and added to 40 (il potassium carbonate (molarity
such that 200 pi of perchloric acid was neutralized by 40 pi potassium carbonate;
referred to henceforth as matched potassium carbonate), mixed and then stored at -40°C
before being analysed for glycogen in duplicate.
The remaining homogenate was centrifuged (1200 g, 4°C, 20 min). A portion (500
pi) of the supernatant was pipetted into a clean 5 ml plastic tube. The pH was adjusted
to 9.0-9.5 using 10 M KOH, the volume made up to 2.5 ml and the samples frozen at -
40°C before measurement of a-glycerophosphate and glycerol concentrations.
A further 2 ml of the supernatant was removed and added to matched potassium
carbonate (400ul), then placed on ice for 30 min and centrifuged (1200 g, 4°C, 20 min).
The supernatant was removed and analyzed for ATP and CP.
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2.2. Biochemical analysis.
A Cobas Bio centrifugal analyser (Eisenweiner et al. 1980) was used for measurement of
glycerol, a-glycerophosphate, ATP, CP and glycogen concentrations.
2.2.1. Glycerol
Glycerol concentrations in perfusate and tissue samples were measured using an
enzymic, fluorimetric method. The method was modified from that of Wieland (1974).
Its principle is shown below.
GK
(a) Glycerol + ATP L-(-)-glycerol-3-phosphate + ADP
GDH
(b) L-(-)-Glycerol-3-phosphate dihydroxyacetone phosphate + NADH + H+
GK = Glycerokinase
GDH = Glycerol-3-phosphate dehydrogenase
Glycerol is phosphorylated by ATP in the presence of glycerokinase to form a-
glycerophosphate. a- glycerophosphate is then converted to dihydroxyacetone phosphate
(DHAP) by glycerophosphate dehydrogenase leading to the formation of NADH.
Plotting of a calibration graph of the increase in fluorescence (excitation wavelength
339 nm, emission wavelength 450 nm) against glycerol standard concentrations allows
determination of glycerol concentrations in samples.
The equilibrium of equation (b) lies far to the left. Therefore, to displace it in the
desired direction the assay was carried out at pH 9.8 and the reaction product, DHAP was
trapped with hydrazine. Samples were analyzed using a Cobas Bio centrifugal analyzer.
A "reagent mixture" was prepared as shown in Table 2.2.
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* From Candida mycoderma (Boehringer Mannheim, 127 795)
A 10 min incubation period of samples with the reagent mixture at 25°C was required
to ensure complete conversion of glycerol to a-glycerophosphate before GDH (170
U/ml; from rabbit muscle, Boehringer Mannheim 127 752) was added to each cuvette.
Glycerol standards were prepared by serial dilution of Precimat glycerol (Boehringer
Mannheim) in double distilled water. Plotting of a standard curve revealed that the
glycerol assay was non-linear (Fig 2.2). The DENS/Plot programme for the Cobas Bio
allowed curve fitting of the fluorescence data of 6 standards, analyzed with each set of
samples to a non-linear standard curve.
Standards:
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Glycerol and a-glycerophosphate were extracted from tissue samples as described in
section 2.1.3. Analysis of tissue extracts using the glycerol method gave the sum of the
glycerol and a- glycerophosphate concentrations. Analysis for a- glycerophosphate as
described in section 2.2.2. and subsequent subtraction of the two results allowed
calculation of the glycerol concentration in the tissue.
Coronary effluent a-glycerophosphate concentrations were found to be below the
detection limit of the assay (0.5 pi) under both normoxic and hypoxic conditions.
Perfusate samples were therefore analyzed for glycerol only.
The range of total glycerol and a- glycerophosphate concentrations in tissue
homogenates was found to be much higher than the range of glycerol concentrations
found in perfusate samples (1-40 pi in tissue vs 0-15 pi in perfusate). Two different
sets of standards were therefore used for tisue and perfusate samples. The standard
concentrations used were 0-200 pi for tissue samples and 0-20 pi for perfusate samples.
The coefficient of variation of the method, calculated by repeated analysis of the 20 pi
standard throughout the studies was 4.7%. Recovery of 50 nmoles glycerol added to 50
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mg heart tissue before deproteinization was 98.4 ± 3.0% (n=12).
2.2.2. L-a-glycerophosphate.
a-Glycerophosphate concentrations in heart tissue were measured using the same
method as for glycerol (Section 2.2.1.), but glycerokinase was omitted from the reaction
mixture.
A series of standards was analyzed simultaneously with every set of samples. A
typical calibration curve is shown in Fig 2.3. The coefficient of variation for the assay,
determined by repeated analysis of the 50 pi standard throughout the study was 2.04%.
Recovery of 50 nmol a-glycerophosphate added to 50 mg heart tissue before
deproteinization was 98.9 ±2.1% (n=12).














Lactate concentrations in coronary effluent were measured using a kit supplied by
Boehringer Mannheim (Kit no. 256 773). The principle of the assay is shown below.
LDH
(a) L-LACTATE + NAD+ « — PYRUVATE + NADH + H+
OPT
(b) PYRUVATE + L-GLUTAMATE^IZZZ=^L-ALANINE + (X-OXOGLUTARATE
LDH = Lactate dehyhrogenase
GPT = Glutamate-pyruvate transaminase.
The second reaction lies far to the right and thus drives the first reaction to completion
by removal of pyruvate. NADH concentration, measured by the absorbance change at
340 nm (37°C), is proportional to the lactate concentration in the sample.
As the kit was designed for measurement of plasma lactate concentrations which are
much higher than perfusate lactate concentrations, the NAD+ concentration used for the
assay was 60% lower than that stated in the kit. All other reagents were made up as
described in the kit. A 1 mM standard solution of lactate was analyzed in triplicate with
every set of samples.
Samples were analyzed using a Cobas Bio centrifugal analyzer. Precinorm S (diluted
1:3) was used as the quality control for the assay. The coefficient of variation of the
lactate assay, calculated by repeated analysis of Precinorm S throughout the study was
5.4%.
2.2.4. Adenosine triphosphate and Creatine phosphate
Tissue ATP and CP concentrations were determined by coupling the enzymic, UV
methods of Lamprecht and Trautschold [1974] and Lamprecht et al. [1974] and adapting
the methods for use on the Cobas Bio. The principle of the method is shown below.
G-6-PDH
(a) Glucose-6-phosphate + NADP +H2O 6-phosphogluconate + NADPH
Hexokinase I
(b) ATP + Glucose ► Glucose-6-phosphate + ADP
Creatine kinase
(c) Creatine phosphate + ADP *- Creatine + ATP
G-6-PDH = Glucose-6-phosphate dehydrogenase
In stage 1, reactions (b) and (a) permit determination of sample ATP by measuring the
increase in absorbance at 340 nm due to formation of NADPH.
CP levels are determined by reactions (c), (b) and (a).
Standards:
Stock ATP: 1 M in neutralized 0.6 M perchloric acid.
Stock CP: 1.5 M in neutralized 0.6 M perchloric acid.
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Table 2.3. Reagent mix for analysis of ATP and CP.
Reagent Final concentration
(mM)
50 mM TEA HC1, pH=7.5-7.6 38.00
0.1 M MgCl2.H20 6.66
0.5 M Glucose 50.00
63 mM NADP (Disodium salt) 0.33
ADP (Disodium salt) 0.15
Glucose-6-phosphate dehydrogenase 723 U/l
*From yeast (Boehringer Mannheim, 127 655)
The reagent mix was prepared immediately before analysis.
The start reagent for the ATP assay was hexokinase 70 U/ml TEA HC1 (From yeast,
Boehringer Mannheim 127 809).
The use of a special mode on the Cobas Bio enabled consecutive measurement of ATP
and CP. The start reagent for the CP assay was creatine kinase 4800 U/ml (From rabbit
muscle, Boehringer Mannheim 126 969).
The inter-assay coefficients of variation for ATP and CP, calculated by repeated
analysis of the 250 |il ATP/375 (il CP standard were 5.8% and 6.1% respectively.
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2.2.5. Glycogen.
Tissue glycogen levels were determined using the UV- enzymic method of Keppler and
Decker [1974], adapted for the Cobas Bio centrifugal analyser. The principle of the
method is as follows. Glycogen is converted to glucose by incubation with
amyloglucosidase at pH 4.8. The glucose formed from this reaction is converted to
glucose-6-phosphate by hexokinase in the presence of Mg^+ and ATP (pH=7.8).
Glucose-6-phosphate is then converted to gluconate-6-phosphate in the presence of
NADP+, resulting in NADPH formation.
The amount of glucose liberated after the hydrolysis of glycogen is proportional to the
NADPH production, measured using the absorbance change at 340 nm (37°C).
2.2.5.(a) Preparation of standards
Glycogen (50 mg) (BDH Chemicals; from mammalian liver) was weighed out and
placed in a 10 ml volumetric flask. Neutralized 0.6 M perchloric acid (5 ml) was added
and the flask was placed in a water bath at 60°C for 10 min. The flask was removed
from the water bath and the solution allowed to adjust to room temperature. The volume
was then made up to 10 ml using neutralized 0.6 M perchloric acid.
A series of 5 standards (0.1 g/1 to 0.5 g/1) were prepared. A portion (200 (il) of each
standard was pipetted in duplicate into 10 ml plastic tubes. Neutralized 0.6 M perchloric
acid acted as a blank. Standards were treated in the same way as the samples throughout
the analysis.
Tissue extracts were prepared as described in section 2.1.3.
Samples and standards were incubated with amyloglucosidase (1 mg/ml; from
Aspergillus niger, Boehringer Mannheim 102 857) dissolved in acetate buffer (0.2 M, pH
4.8) for 2 h at 40°C.
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After incubation, 0.6 M perchloric acid (0.5 ml) was added and the samples left on ice
for 15 min. Matched potassium carbonate (0.1 ml) was then added and the samples left
on ice for a further 30 min. The tubes were centrifuged (4°C, 15 min, 1200 g) and the
supernatant removed to Cobas Bio cups for glucose analysis.
2.2.5.(b) Glucose analysis.
Preciset-D-Glucose (Boehringer Mannheim) 0.505 mM was used as the standard for
the glucose assay.
Precinorm S (Boehringer Mannheim) diluted 1:24 in neutralized 0.6M perchloric acid
acted as a quality control for the assay.
Glucoquant Test Combination (Boehringer Mannheim) was used as the start reagent for
the glucose assay.
The coefficient of variation of the assay, calculated by repeated analysis of the 0.1 g/1
standard was 2.9%. Recovery of 0.1 mg glycogen glucose was 90.7±5% (n=20).
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2.2.6. Triacylglycerol.
2.2.6.(a) Extraction and separation of lipids.
Freeze-dried heart tissue was pulverized as described in section 2.1.2. and each sample
transferred to a quickfit tube (20 x 125 mm). Internal standard (0.2 mg triheptadecanoin
in 1 ml chloroform) was added to each tube. A "blank" containing internal standard
only was analysed simultaneously with each set of samples.
Lipids were extracted according to the method of Folch et al. (1957) using 29 ml
chloroform: methanol (2:1 v/v).
The lipid extract was poured into a 11 Buchi flask and dried down under partial vacuum
using a Buchi-R rotary evaporator over a water bath at 30°C. The lipids were
redissolved in 6 ml chloroformmethanol (2:1 v/v) and poured into a quickfit tube.
Samples were then dried down under vacuum and 1.0 ml chloroformmethanol (2:1 v/v)
was added using a Hamilton syringe.
A portion of each extract (400 pi) was pipetted into a clean quickfit tube and applied as
a 5 cm band on precoated silica gel 60 t.l.c. plates (Merck 5721; 20x20 cm). The
remainder of the extract (600 pi) was stored at -40°C in case repeat analysis was
required. Plates were developed in a tank containing hexane:diethylether:formic acid
(80:20:2 by vol.) at room temperature for about 1 h or until the solvent front approached
the top of the plate. Plates were then removed from the tank, air dried and sprayed with
POPOP/PPO (6mg 1,4 bis [2-(5-phenyloxozolyl) benzene and 10 mg 2,5-
Diphenyloxazole in 100 ml chloroform).
Bands were visualized under UV light at 365 nm. A typical separation is shown in Fig
2.4. The band, previously identified using known standards, was scraped from the plate
and placed in a tube.
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Base (0.5 M sodium methoxide) catalyzed transmethylation was carried out as
described by Christie (1982). The methylesters were redissolved in 25 |il chloroform
and transferred to GLC vials flushed with nitrogen and stored at -20°C prior to analysis.
2.2.6.(b) Gas Liquid Chromatography.
A Pye Unicam series 204 gas chromatograph fitted with a PU4700 autoinjector and
linked to a Trilab Model II integrator (Trivector) was used. A glass column (1.5 m long,
I.D. 2mm) packed with a stationary phase of 10% SP2330 on 100/120 mesh chromosorb
WHW (Supelco) was used for all separations.
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Hydrogen gas flow 50 ml/min
Carrier gas flow 50 ml/min






Solutions of methyl esters stored at -20° were allowed to equilibrate to room
temperature before each sample (1 |il) was injected onto the column.
After visual inspection for correct separation of fatty acid peaks and baseline tracking,
the samples were reanalysed where necessary.
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2.2.7. Separation of Radioactive Phospholipids.
Phospholipids, extracted from heart tissue as described in section 2.2.6.;were separated
by t.l.c. using LK5 plates with a pre-adsorptive area (Whatman catalogue No. 4855 820
(20 x 20 cm). The plates were impregnated with 1.2% boric acid and reactivated at
100°C for 60 min (Fine and Sprecher 1982).
Lipid extract (500 |il) was spotted onto the plates. The plates were developed in
chloroform:methanol:water:ammonia (120:75:6:2 by vol.) in a paperlined tank at room
temperature. The plates were developed for about 1 h, air dried, and sprayed with
dichlorofluorescein (0.1%). The phospholipid fractions were then visualized under UV
light at 365 nm. A typical separation is shown in Fig 2.5. The position of each band
had been previously identified using known standards. Each band was scraped off and
placed in a liquid scintillation counting vial. Scintillation solution (10 ml) was added to
each sample and samples were counted as described in section 2.2.8.
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2.2.8. Liquid scintillation counting.
Samples were placed in Sarstedt scintillation counting vials (58 x 27 mm) and 10 ml of
scintillation solution (Scintran, Cocktail T; BDH Chemicals 14509) was added. [^H]
labelled toluene internal standard (Dupont NES-004 and NES-006 respectively) were
added to each sample in order to account for quenching. Efficiency of [^H] counting
was 28±2%.
2.2.8.a) Fractionated lipid samples
Fractionated lipid samples (Section 2.2.7.) were counted for 10 min.
2.2.8.b) Perfusate samples
Each perfusate sample (1 ml) was counted for 20 min. A further portion of each
sample (1 ml) was placed in a Sarstedt tube and [^F^O] evaporated by placing in a water
bath at 70°C for 3 h. Each sample was then redissolved in cold perfusate (1 ml) and
then counted for 20 min as above.
Unlabelled glycerol (30 (il; 100fiM) was added to all samples prior to evaporation of
water to prevent loss of [^H]-glycerol.
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2.2.9. Measurement of Noradrenaline.
Noradrenaline concentrations in perfusate and tissue samples were measured
radioenzymatically (DaPrada and Zurcher 1976).
Noradrenaline was converted to its 3-0-methylated derivative (normetanephrine) using
catechol-O-methyl transferase (COMT) in the presence of the radioactive methyl donor
3H-methyl-5-adenosylmethionene (^H-SAM) as shown below.
The product of the reaction (normetanephine) was purified by selective ion pair
extraction with tetraphenylborate, separated by t.l.c. and subsequently oxidized to
vanillin. The final product was counted in a liquid scintillation counter. (LKB 1217
RACKBETA). All chemicals were from BDH and the standards from Sigma. The
COMT (prepared from rat liver) was stable when stored at -20°C for at least 6 months
(Forfar 1985).
2.2.9.a) Perfusate samples
Perfusate (500 pi) was stabilized with 0.6M perchloric acid (500 pi) plus EGTA (2
g/100 ml), and stored at -40°C before analysis. The concentrations of the standards used





Freeze-dried hearts were pulverized as described in section 2.1.3. Heart tissue
(approximately 10 mg) was weighed. The tissue was transferred to a Beckman tube and
1 ml 0.3M perchloric acid was added. The sample was mixed and then centrifuged
(20000 g, 5 min) using a Hettich Mikroliter centrifuge (Arnold R Howell Ltd, London).
The supernatant was stored at -40°C before analysis.
The coefficient of variation for the assay was 7% (Forfar 1985).
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2.3. Expression of results and statistical analysis.
Concentrations were expressed as amounts per gram wet weight of tissue throughout.
A dry:wet weight ratio of 5:1 was used as the conversion factor where necessary.
An unpaired Student t-test was used to indicate significant differences between groups.
All results were presented as Mean±SEM. As myocardial triglyceride values were not
normally distributed, this data was presented as median (95% confidence intervals) and
was normalised (log value) before statistical analysis. MINITAB statistics package
(CLE.COM Ltd, Edgebaston) was used for all statistical analysis. The experiments were
carried out using a rigorous protocol throughout, hence there were no missing data. The
number of observations used in calculation of SEMs and for statistical analysis did not
differ from those stated in the methods section of each chapter and were therefore not
repeated in tables or figures.
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2.4. Calculation of RQ values
RQ values are a useful index in determining the main substrate being oxidized by a
tissue. As both arterial and venous pH, PO2 and PCO2 could be measured using this
model, in theory it should be possible to calculate RQ values for each experiment.
Values may be calculated as follows:
Oxygen uptake = [(P02a-P02v) x a x b] / 25.4 mM
P02a= Arterial PO2
P02v= Venous PO2
a = Solubility of oxygen in buffer at 37°C (0.003ml 02/lOOml buffer per mmHg)
b = Coronary flow rate (ml/min)
25.4 = Volume of ideal gas at 37°C
CO2 production may be calculated by subtracting the sum of the concentrations of
dissolved carbon dioxide and bicarbonate in the arterial perfusate from that in the venous
perfusate:
H2C03= [PC02 x c x b] / 25.4
c = Solubility of CO2 in buffer at 37°C (0.078 ml CO2/IOO ml buffer per mmHg)





= pIC + log ([HC03]/[C02])
= 6.1
Therefore:
[HCO3 ] = H2CO3 x antilog(pH - 6.1) mM
= (0.0348 PC02) x antilog(pH - 6.1) mM
Total C02 = [H2C03] + [HCO3]
C02 production = Total C02v - Total C02a
where a = arterial and v = venous.
Using data from a typical experiment:





= (40 x 0.078 x 10/25.4)
= 1.22
= 1.22 x 19.5
= 23.95 mM
= 23.95 + 1.22
= 25.17 mM
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[H2C03 ]v = (45.8 X 0.078 x 10) / 25.4
= 1.41 mM
[HCQ3]V = 1.41 x 15.49
= 21.84 mM
Total [CC>2]v = 1.41 + 21.84
= 23.25 mM




This value is obviously not a true RQ value. The error in calculating the value is
presumably due to the effects of hypoxia. The increased production of hydrogen ions
during hypoxia will neutralize bicarbonate ions in the perfusate leaving the heart. This
will affect the PC02 and pH. Variability of these parameters in turn will affect the
calculated RQ value. It therefore appears that although RQ values may be calculated,
the parameters measured in this study are not sufficiently reliable to provide a realistic




INCREASING SEVERITY OF HYPOXIA
ON MYOCARDIAL METABOLISM.
3.1. Introduction.
A substantial amount of evidence favours the likelihood of the operation of an energy
wasting TAG- NEFA cycle during acute myocardial ischaemia (Section 1.7). However,
little information is available in terms of the proportion of energy used by the cycle and
its relative importance during oxygen deprivation.
The hypoxic isolated, perfused rat heart is a useful model for obtaining quantitative
information about the biochemical changes taking place in the heart during oxygen
deprivation (Section 1.6). The aim of this study was to use the model to examine the
biochemical consequences of varying severities of hypoxia with particular regard to the
operation of the TAG-NEFA wasteful cycle and its potential importance in the
development of arrhythmias.
The use of the isolated, perfused rat heart inevitably entails a period of anoxia in the
interval between removing the heart and commencing perfusion. This period obviously
has biochemical consequences. If the effects of this period of anoxia are prolonged, they
need to be considered when analyzing data. A preliminary study was therefore also
carried out to look at the response of the heart to this period of anoxia and to try and




Hearts from male Sprague Dawley rats (body weight 400-450 g) were removed and
perfused normoxically (95%C>2/5%C02) for 40min. Coronary effluent samples were
collected at t=l, 2, 3, 4, 5, 6, 8, 10, 15,20, 25, 30, 35 and 40 min and analyzed for
glycerol and lactate.
3.2.2. The effects of increasing severity of hypoxia on myocardial metabolism.
Hearts from male Sprague Dawley rats (body weight 400-450g) were removed and
perfused as described in section 2.1.2.
Four groups of rats were perfused normoxically (95%02/5%CC>2) for 30 min followed
by a further 30 min period of hypoxic perfusion. The oxygen tension of the perfusate
for each group (Mean±SD) is shown in Table 3.1.
Table 3.1. Oxygen tension of the perfusate with varying gas compositions.
Group No. of hearts Composition of gas ^2 (tnmHg)
A 18 95%02/5%C02 60016
B 16 30%02/65%N2/5%C02 220±6
C 7 20%02/75%N2/5%C02 133±8
D g 10%02/85%N2/5%C02 58±g
For the sake of convenience, groups B, C and D will henceforth be referred to as mild,
moderate and severe hypoxia groups respectively.
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Coronary effluent samples were collected at 5 min intervals and analyzed for glycerol
and lactate as described in sections 2.2.1 and 2.2.2 respectively. Oxygen uptake was
monitored throughout the experiments. Tissue samples were analyzed for glycogen,
ATP, CP, a-glycerophosphate, glycerol and triacylglycerol (TAG) as described in
Chapter 2.
Hearts were removed from a fifth group of rats, normoxically perfused for a few





Both lactate and glycerol release were elevated immediately after commencing
perfusion. Efflux of both of these metabolites gradually decreased between t=l and t=20
min, after which a low, stable rate of lactate and glycerol release continued for the
remainder of the perfusion period (Figs 3.1 and 3.2 respectively).
In the light of these results it was decided to include a preperfusion period of 20 min
duration in subsequent experiments before collection of the first coronary effluent
sample. Any hearts in which basal lactate release was greater than 1.5 jxmol.g'^wet
wt.min"! were considered to be bad preparations and were therefore discounted from the
results.








0 10 20 30 40 50
TIME (min)
Lactate release is expressed as nmol.g'^min"!.
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Figure 3.2. Glycerol release from a typical heart during the first 40 min after
TIME (mln)
Glycerol release is expressed as nmol.g'^min"!
3.3.2. Effects of increasing severity of hypoxia on myocardial metabolism.
Glycerol and lactate efflux from the normoxically perfused hearts (control) remained
constant throughout the 60min perfusion period. In contrast, hypoxia resulted in a
significant increase in glycerol and lactate release (Figs 3.3 and 3.4 respectively). The
total glycerol release between t=30 and t=60min, calculated by measuring the area under
the curve of glycerol release vs time for each group is shown in Fig 3.5.
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Glycerol release is expressed as nmol.g"* wet wt. min'l (Mean±SEM).
*P<0.01 vs CONTROL (Analysis of variance).
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Lactate release is expressed as nmol.g'^min'^ (Mean±SEM)
* PcO.Ol vs CONTROL (Analysis of variance)
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Figure 3.5. The influence of severity of hypoxia on glycerol release from the isolated,
perfused rat heart over a 30 min period.
Glycerol release is expressed as nmol.g"^30min"l (Mean±SEM)
** P<0.01 vs NORMOXIA (t-test).
Oxygen uptake had decreased significantly on collection of the first sample for blood
gas analysis (t=35min) after the change to hypoxic perfusion. The mean oxygen uptake
for each group is shown in Table 3.2. Oxygen uptake did not vary with time during the
experimental period.
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Table 3.2. The influence of severity of hypoxia on myocardial oxygen uptake.
Group % OXYGEN Oxygen Uptake
(mmol.g'lmin'l)




Results are presented as MeaniSEM.
Measurements of tissue high energy phosphate levels revealed a significant decrease in
ATP at each level of hypoxia in the experimental groups compared with the control
group. ATP was significantly lower in the moderate hypoxia group than in the mild
hypoxia group but there was no further decrease in ATP level when hearts were
subjected to severe hypoxia.
After mild hypoxia no significant change in tissue CP concentration could be found
when compared with the control group (2.2810.04 (imol.g'lwet wt. mild hypoxia vs
2.5610.02 control; MeaniSD). However, both the moderate hypoxia and severe
hypoxia groups exhibited significantly lower CP levels than the control group. The CP
concentration of the severe hypoxia group was significantly lower than that of the
moderate hypoxia group (Fig 3.6). Tissue glycogen levels followed a similar pattern to
CP levels (Fig 3.7).
77
Figure 3.6. The influence of severity of hypoxia on high energy phosphate
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NORMOXIA MILD MODERATE SEVERE
HYPOXIA HYPOXIA HYPOXIA
Metabolite concentrations are expressed as (imol.g'^wet wt. (Mean±SEM)
♦ PcO.Ol vs NORMOXIA
a PcO.Ol vs MILD HYPOXIA
b PcO.Ol vs MODERATE HYPOXIA
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Hypoxia resulted in a significant increase in myocardial tx-glycerophosphate
concentrations. The mean a-glycerophosphate concentration in hearts subjected to
moderate hypoxia group was significantly higher than in those subjected to mild hypoxia
group, but there was no difference between the levels in the moderate hypoxia and severe
hypoxia groups (Fig 3.8).
Figure 3.8. The influence of severity of hypoxia on a-glycerophosphate










NORMOXIA MILD MODERATE SEVERE
HYPOXIA HYPOXIA HYPOXIA
a-glycerophosphate concentrations are expressed as (imol.g'^wet wt. (Mean±SEM)
* PcO.Ol vs NORMOXIA (t-test)
a PcO.Ol vs MILD HYPOXIA (t-test)
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Myocardial TAG levels varied considerably within groups. As the results were not
normally distributed, statistical analysis was performed using logarithms of the values.
No significant difference in tissue TAG concentrations between groups was found (Table
3.3).
Table 3.3. The influence of severity of hypoxia on myocardial TAG concentrations.
% OXYGEN TAG concentration ((imol.g'^wet wt.)
95 0.5 (0.2, 1.9)
30 0.5 (0.2, 2.2)
20 0.5 (0.2, 2.0)
10 0.4 (0.1, 1.2)
Results are presented as Median (95% Confidence limits).
Biochemical analysis of the preperfusion control group of hearts and comparison with
the normoxically perfused hearts (group A) revealed that a significant amount of TAG,
and CP are utilized by the heart under normoxic conditions (Fig 3.9).
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Figure 3.9. The influence of normoxic perfusion (60 min) on metabolite
concentrations in rat heart ventricle.
20 ,
[METABOLITE] 10
ATP CP GLYCOGEN GP TAG
□ PRE-PERFUSION
□ AFTER PERFUSION
Metabolite concentrations are expressed as p.mol.g-1 wet wt. (Mean±SEM)
*P<0.01 vs PRE-PERFUSION (t-test)
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3.4. Discussion.
The elevated lactate and glycerol release during the first few minutes of the perfusion
period is presumably the result of a shift from aerobic to anaerobic respiration during the
period of anoxia on removal of the heart. Lactate and glycerol production are thought to
reflect anaerobic glycolysis and lipolysis respectively. Placing the heart in ice cold
perfusate immediately after removal helps to minimize the effects of anoxia by "slowing
down" the biochemical changes in the heart, inhibiting contraction and therefore
preventing excessive loss of energy supplies and endogenous substrates. The high rates
of lactate and glycerol release during the first few minutes of perfusion probably reflect
the wash-out of lactate and glycerol accumulated during the anoxic period.
Endogenous triacylglycerol is utilised in the isolated, perfused rat heart under normoxic
conditions despite the presence of 5.5 mM glucose as an exogenous substrate (Fig 3.9).
This is in agreement with the findings of Neely et al.. (1970) and De Groot et al.. (1989).
The decrease in CP observed during normoxic perfusion implies that oxygenation of the
tissue was inadequate for the control group. It is well recognized that perfusion of
isolated hearts may not provide the optimum requirements for the maintenance of aerobic
metabolism.
The metabolic changes observed in the experimental groups are typical of the
biochemical changes expected to occur during oxygen deprivation (Chapter 1).
When the oxygen supply to the heart is reduced the decreased capacity of the tissue for
oxidative metabolism leads to inhibition of ATP production and accumulation of reduced
flavin and nicotinamide co-enzymes in the mitochondria. The NADH/NAD"1" ratio
subsequently increases and ADP and AMP levels increase. As a consequence of these
changes, the rate of glycolysis increases and entry of pyruvate into the citric acid cycle is
hindered. Hence lactate production by the tissue is increased.
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Under mild hypoxic conditions the glycogen concentration in the heart did not decrease
significantly compared with the control group of hearts. This may be a consequence of
stimulation of both glycogen phosphorylase and glycogen synthetase during oxygen
deprivation (Williams and Mayer 1966, Opie 1968). In contrast, tissue glycogen levels
in the moderate and severe hypoxia groups were significantly lower than the control
group, implying a shift towards increased glycogen breakdown and inhibition of
glycogen synthesis during more severe hypoxia, possibly due to lack of availability of
high energy phosphates for glycogen synthesis.
At low glycogen concentrations disruption of the glycogen particle and associated
enzyme system may occur, thereby removing accessibility to phosphorylase (Entman et
al. 1977). Alternatively, in the severe hypoxia group, the glycogen remaining in the
heart may contain insufficient a-1-4 linkages, preventing breakdown of glycogen by
phosphorylase (Bailey et al. 1982).
As the amount of glucose taken up by the heart is small in comparison with the
concentration in the perfusate, glucose uptake cannot be measured accurately owing to
the large errors in attempting to evaluate such small changes in concentration. However,
glucose uptake is well known to increase during oxygen deprivation (Morgan et al.
1961). Under mild hypoxic conditions, it may be that the stimulation of glucose uptake
is sufficient to maintain the increase in glycolytic rate, whereas with more severe hypoxia
although glucose transport into the heart is augmented, this may not be adequate in
providing substrate for the increased glycolytic activity without depleting endogenous
glycogen supplies (Morgan et al. 1959, Morgan et al. 1961). As neither glucose uptake
nor the relative activities of glycogen synthetase nor glycogen phosphorylase were
measured, this question cannot be answered conclusively.
After mild hypoxia, tissue ATP concentrations were depleted compared with the
control group, but CP levels were unchanged. This was unexpected as CP is thought to
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be depleted in preference ATP during oxygen deprivation (Neely et al.1973, Hearse
1979). In this case the increase in ATP production via anaerobic glycolysis may have
been adequate to maintain levels at a sufficient level so that CP stores were not utilized.
The fact that CP concentrations in the severe hypoxia group were significantly lower
than in the moderate hypoxia group , whereas ATP concentrations were not different in
the moderate and severe hypoxia groups is consistent with the generally held view that
CP acts as an "emergency" store of high energy phosphate for use during severe energy
depletion (Opie 1984). Hence, during more severe hypoxia, utilization of CP appears to
preserve ATP. Glycolytically produced ATP may be preferentially available for
maintenance of ionic gradients (Harris and Barry 1984, McDonald and MacLeod 1973,
Mercer and Durham 1981). The loss of this source of ATP production could conceivably
have lethal consequences.
The increase in glycerol release from the heart during hypoxia is commonly used as an
index of myocardial lipolysis (Christian et al. 1968, Stam et al. 1979, Stam and
Hulsmann 1982, Severson et al. 1986, De Groot et al. 1989). Hypoxia is thought to
stimulate release of endogenous catecholamines (Wollenberger and Shahab 1965,
Karwatowska-Krynska and Beresewicz 1983) which activates a hormone sensitive TAG
lipase in the heart by phosphorylation via a cAMP- protein kinase cascade system
(Section 1.6.1).
If the glycerol released from the heart during hypoxia does reflect TAG breakdown, for
every mole of glycerol leaving the heart, 3 of non-esterified fatty acid (NEFA) remain in
the tissue. As no albumin was present in the perfusate, NEFA were unable to leave the
heart. Furthermore, due to the decreased oxygen supply to the tissue, oxidation of
NEFA is inhibited. NEFA are therefore likely to accumulate in the tissue. TAG
concentrations in the heart were unchanged after hypoxia compared with normoxia
despite the large increase in glycerol release implying that NEFA were re-esterified.
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The within-group variation in TAG levels may reflect varying proportions of
intermyocardial adipocytes in the hearts. Extraneous adipose tissue was removed before
ffeeze-clamping hearts but no measure of the proportion of adipocytes within the heart
was available. However, similar results have been obtained from experiments in which
isolated myocytes were subjected to hypoxia (Larsen et al. 1989), suggesting that the
presence of adipocytes within the heart does not significantly affect the conclusions
drawn from these experiments.
Re-esterification of NEFA requires the presence of a-glycerophosphate. a-
glycerophosphate levels increased as the severity of hypoxia increased. This was
expected as the increased NADH/NAD+ ratio during oxygen deprivation favours
conversion of dihydroxyacetone phosphate to a-glycerophosphate. a-glycerophosphate
may also be formed by phosphorylation of glycerol by the action of glycerokinase. The
activity of this enzyme in rat heart is commonly dismissed as being negligible.
However, the existence of the enzyme in rat heart has been demonstrated (Robinson and
Newsholme 1967), its maximum activity being 10.8 nmol glycerol g~* fresh wt. min'l.
This activity was measured in the presence of relatively high glycerol concentrations
(50|iM) and was diminished by AMP and ADP, both of which are likely to increase in
concentration during hypoxia. However, as neither glycerokinase activity nor ADP and
AMP concentrations were measured under the conditions used in this study, the possible
contribution of glycerokinase activity to a-glycerophosphate production should not be
dismissed.
Given that 2 high energy phosphate groups are required for conversion of each NEFA
to fatty acyl CoA prior to re-esterification, a total of 6 moles of ATP are required for
each mole of TAG synthesized. Assuming that
1) 3 NEFA remain in the heart for every glycerol molecule released.
2) No NEFA oxidation takes place
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3) The P/0 ratio is 3,
the total aerobic and anaerobic ATP production may be calculated from the oxygen
uptake and lactate release respectively and the proportion of ATP required to re-esterify
the NEFA may be calculated from the glycerol release for each group of hearts. The
potential proportion of energy used in TAG-NEFA cycling is shown in Table 3.4.
























ATP production is expressed as pmol.g"^30min"l (MeaniSEM).
Obviously these percentages are only approximations of the possible energy wastage.
Some degree of NEFA oxidation cannot be ruled out, particularly in the mild hypoxia
group. Unfortunately the relative contribution of the various substrates to the total ATP
production could not be determined due to difficulty in calculating RQ values (section
2.4).
It is also possible that uncoupling of oxidative phosphorylation takes place during
hypoxia. Conversion of NEFA to acyl CoA and a subsequent increase in size of the acyl
CoA pool is also possible. High concentrations of acyl CoA may inhibit adenine
nucleotide translocase, the enzyme responsible for transporting ATP from within the
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mitochondria to the cytoplasm. (Ho and Pande 1974, Shug and Shrago 1973). This
would mean that any ATP formed by oxidative phosphorylation would not be available
for re-esterification of NEFA and for other energy-requiring processes in the myocyte.
Even if only glycolytically produced ATP is available for the re-esterification process,
the loss of energy due to TAG-NEFA cycling during severe hypoxia amounts to less than
7% of the available ATP.
The proportion of energy wasted increases as the severity of hypoxia increases.
During ischaemia when the blood supply to an area of tissue is prevented, an oxygen
gradient exists across the tissue. A range of hypoxic states therefore exist - the outer
edge of the ischaemic zone being mildly hypoxic and the centre of the ischaemic zone
being severely hypoxic. It is therefore probable that TAG-NEFA cycling occurs at
different rates across the ischaemic area. The heterogeneity of blood flow to an area of
tissue is an important factor in the development of arrhythmias. Varying rates of
wasteful cycling in an area of myocardium may therefore contribute to arrhythmogenesis.
In the severe hypoxia group in this study, glycolytically produced ATP accounted for
as much as 85% of the total ATP produced, therefore making a highly significant
contribution to myocardial energy production. Under ischaemic conditions glycolysis is
inhibited and this source of ATP is therefore dramatically reduced. Hence these results
cannot be directly extrapolated to ischaemia. In addition, the supply of oxygen and
substrates remains constant during hypoxia whereas in ischaemia, oxygen and substrates
are rapidly depleted and are only partly replaced. However, this study provides further
evidence in favour of the operation of a TAG-NEFA cycle during myocardial hypoxia.
The amount of energy consumed in the operation of the TAG-NEFA cycle during
hypoxia does not appear to cause a significant drain of ATP supplies, suggesting that the
cycle is not likely to be a major cause of arrhythmias. However, further experiments are
needed to examine the effect of ischaemia on the operation of the TAG-NEFA cycle and
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to study possible differences in rates of cycling in different parts of the cell. It is possible
that the TAG-NEFA cycle plays an important role in protecting the hypoxic myocardium




THE INFLUENCE OF MYOCARDIAL TRIACYLGLYCEROL
LEVELS ON TAG-NEFA CYCLING DURING NORMOXIA AND
HYPOXIA
4.1. Introduction.
Raised myocardial TAG levels may increase susceptibility of the heart to ischaemic or
hypoxic damage. Endogenous catecholamines are thought to be released during hypoxia
in the isolated, perfused heart (Wollenberger and Shahab 1965, Karwatowska-Krynska
and Beresewicz 1983) and ischaemia (Dart et al. 1987, Schomig et al. 1987). Brownsey
and Brunt (1977) increased TAG levels in rat hearts by feeding a high fat diet. These
hearts were found to exhibit
1) An increased rise in resting tension and decline in heart rate during ischaemia
compared with hearts from rats with normal myocardial TAG levels.
2) An increased incidence of arrhythmias and a greater tendency to deteriorate in
mechanical performance in the presence of adrenaline.
Hearts from diabetic rats are more vulnerable to anoxia than normal rat hearts (Hearse
et al. 1975). This increased susceptibilty to injury may be due to the greater accumulation
of endogenous TAG (Denton and Randle 1967). Isolated, perfused hearts from obese rats
which also have raised TAG levels are more susceptible to arrhythmias than hearts from
lean rats (Sargent 1990).
Trach (1986) suggested that TAG-NEFA cycling may become more important as a
cause of arrhythmias when TAG levels in the heart are increased. In accordance with
this view, basal and hormone-stimulated lipolysis are increased when tissue TAG levels
are raised (Stam and Hulsmann 1978, Hulsmann et al. 1979).
Cardiac denervation is known to be protective against ischaemic arrhythmias (Ebert et
al. 1970, Martin and Meesman 1985). In hearts from denervated rats, myocardial
lipolysis, demonstrated by glycerol efflux, was not activated during ischaemia (Hough
and Gevers 1975), supporting the hypothesis that TAG metabolism may be
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involved in the development of arrhythmias.
Extraction of NEFA by the myocardium rises with the plasma NEFA/albumin ratio
(Evans et al. 1963, Miller et al. 1976). Because the plasma albumin concentration is
fairly constant, the rate of uptake is largely determined by the arterial concentration of
NEFA (Carlsten et al. 1961, Vik-Mo et al. 1979). In ischaemic myocardium, (3-
oxidation is impaired, and increased NEFA extraction therefore results in accumulation
of TAG in the tissue (Scheuer and Brachfield 1966, Opie et al. 1973, Jesmok et al. 1978).
Chronic ischaemia may thus led to TAG accumulation (Brachfield 1969) and could in
this way lead to a decrease in tolerance to ischaemic or catecholamine- induced stress.
The purpose of this study was to examine the effects of conditions associated with
raised myocardial TAG levels, i.e. fasting (Wittels and Bressler 1964, Denton and Randle
1967) and obesity, on the rate of TAG-NEFA cycling during hypoxia, and also, as age is
known to be a risk factor for increased vulnerability to hypoxia (Nakanishi et al. 1984),
to compare the rates of TAG-NEFA cycling in hearts from rats of different ages.
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4.2. Methods.
Hearts from three groups of male Sprague-Dawley rats and one group of inbred obese
rats (ob/ob; supplied by The Rowett Researh Institute, Aberdeen) were studied. The
characteristics of each group of rats was as follows:
A. Control (Body weight 450-500g; 18-20 weeks). Fed ad libitum; n=18 normoxia,
n=16 hypoxia.
B. Young (Body weight 280-320g; 12-14 weeks). Fed ad libitum; n=6 normoxia, n=6
hypoxia.
C. Fasted (48 h; initial body weight 450-500g). Water ad libitum; n=6 normoxia, n=6
hypoxia.
D. Obese (Body weight 500-550g; 18-20 weeks). Fed ad libitum; n=6 normoxia, n=9
hypoxia.
Rats were anaesthetized and the hearts removed and perfused. The protocol was as
described in Section 2.1.2. All hearts were normoxically (95%02/5%CC>2) perfused for
30 min, after which hearts were subjected to either a further 30 min normoxia or 30 min
hypoxia (30%C>2/65%N2/5% C02).
Coronary effluent was collected at 5 min intervals and analyzed for glycerol and
lactate. Oxygen consumption was monitored throughout. After perfusion, hearts were
freeze-clamped, freeze-dried and the tissue was analayzed for ATP, CP, glycogen, a-
glycerophosphate, glycerol and triacylglycerol as described in Chapter 2.
Additionally, hearts from control, young and fasted rats were freeze-clamped
immediately after suspension and wash-out of blood (n=6 per group) to obtain
comparison of metabolite concentrations between groups before perfusion. These hearts
were also freeze-dried and analyzed as described above.
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4.3 Results.
Body weights of rats fasted for 48 h decreased by 49.5±4 g (MeaniSEM; P<0.05, t-
test).
TAG levels in hearts from fasted rats were not significantly different than in hearts
from fed (control) rats (Table 4.1). The only significant differences between hearts from
control and young rats were in the tissue ATP and CP concentrations. Hearts from
young rats had significantly lower ATP concentrations but significantly higher CP
concentrations than the control group. However, the total high energy phosphate (ATP
+ CP) concentrations were not significantly different.
As reported by other workers, glycogen concentrations were significantly higher in
hearts from fasted rats (28±0.6 fasted vs 18±0.3 pmol glucose equivalents g'^wet wt
fed). The amount of a-glycerophosphate in hearts from fasted rats was significandy
lower than in fed rats (Table 4.1).
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Table 4.1. Concentrations of metabolites in hearts from control,young and fasted
rats before perfusion.
METABOLITE CONTROL YOUNG FASTED
ATP 5.10±0.05 4.63±0.11* 4.3810.20
CP 4.49±0.10 4.9210.12* 3.7010.32
GLYCOGEN 18.40±1.20 18.2710.78 27.5611.37**
a-GP 2.02±0.45 1.7210.45 0.0510.02**
GLYCEROL 0.06±0.01 0.0610.01 0.0510.01
TAG 2.4010.10 2.4810.10 2.1810.12
Metabolite concentrations are expressed as |imol.g"^wet wt. (Mean±SEM).
Glycogen concentration is expressed as glucose equivalents.
a-GP = a-glycerophosphate.
* P<0.05 vs CONTROL
** P<0.01 vs CONTROL
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All groups of hearts released similar amounts of glycerol during normoxia (Fig 4.1).
In all cases, hypoxia resulted in a significant increase in glycerol release. Hypoxia-
stimulated glycerol efflux was significantly lower in hearts from young and fasted rats
than in hearts from control (fed) rats.
Figure 4.1. The influence of age, fasting (48 h) and obesity on glycerol release from










CONTROL YOUNG FASTED OBESE
□ NORMOXIA
□ HYPOXIA
Glycerol release is expressed as nmol.g'^wet wt.per 30 min (Mean±SEM)
**P<0.01 vs NORMOXIA (t-test)
aaP<0.01 vs CONTROL (t-test)
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Lactate release from the normoxic heart was reduced in fasted and obese rats compared
with hearts from fed, lean rats of similar age (control) (Fig 4.2). As expected, hypoxia
resulted in a significant increase in lactate release from all groups of hearts. The amount
of hypoxia-stimulated lactate release was similar in hearts from young, fasted and obese
rats. This was significantly lower than lactate release from control hearts.
Figure 4.2. The influence of age, fasting (48 h) and obesity on lactate release from








CONTROL YOUNG FASTED OBESE
□ NORMOXIA
□ HYPOXIA
Lactate release is expressed as (imol.g"^ wet wt. per 30 min (Mean±SEM)
*P<0.01 vs NORMOXIA (t-test)
aP<0.05 vs CONTROL (t-test)
a aP<0.01 vs CONTROL (t-test)
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Oxygen uptake during normoxia was significantly lower in hearts from fasted rats than
in hearts from fed rats. Hypoxia caused a significant decrase in oxygen uptake in all
groups of hearts, none of the groups showing significant differences (Table 4.2.).
Table 4.2. Oxygen uptake by hearts from control, young, fasted and obese rats
during normoxia and hypoxia.






Results are expressed as Mean±SEM
**P<0.01 vs Normoxia (t-test)
aa PcO.Ol vs Control (fed) (t-test)
Each group showed a decrease in ATP and an increase in a-glycerophosphate
concentration in the heart after hypoxia. CP, glycogen and TAG concentrations were
not significantly affected by hypoxia. Tissue ATP concentrations in hearts from young
rats were significantly higher than in hearts from control rats after normoxic perfusion
(Table 4.3). However, this difference was no longer observed after hypoxia. Other




Table 4.3. The influence of normoxic and hypoxic perfusion on metabolite
concentations in hearts from control and young rats.
CONTROL YOUNG
Normoxia Hypoxia Normoxia Hypoxia
ATP 4.13±0.2 2.99i0.2aa 5.1110.3* 3.32i0.3aa
CP 2.50±0.1 2.2810.2 3.2610.4 2.9910.3
GLYCOGEN 11.8811.3 10.6310.9 7.8011.4 8.5711.9
a-GP 0.6810.1 1.5210. iaa 0.5110.2 0.5010.2^
GLYCEROL 0.3210.1 0.0010.0 0.4510.2 1.0810.1
TAG 0.50 (0.2,1.9) 0.50 (0.2,2.2) 0.40(0.3,1.1) 0.60 (0.4,1.6)
Metabolite concentrations are expressed as (imol.g'l wet wt. (Mean±SEM), except TAG
concentrations which are expressed as Median (95% Confidence limits).
Glycogen concentration is expressed as glucose equivalents, a-GP = a glycerophosphate.
* P<0.05 vs CONTROL (t-test)
aa PcO.Ol vs Normoxia (t-test)
Although fasted rats exhibited elevated myocardial glycogen concentrations before
perfusion, glycogen utilization rates were significantly higher in hearts from fasted rats
after both normoxic and hypoxic perfusion than in hearts from fed rats, as demonstrated
by the significantly lower glycogen concentrations in hearts from fasted rats after
perfusion (Table 4.4). The a-glycerophosphate concentration in fasted rat hearts was
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significantly lower after normoxic perfusion but not different than in hearts from fed rats
after hypoxic perfusion (Table 4.4).
Table 4.4. The influence of normoxic and hypoxic perfusion on metabolite
concentrations in hearts from control and fasted rats.
CONTROL FASTED
Normoxia Hypoxia Normoxia Hypoxia
ATP 4.1310.2 2.99i0.2aa 4.1210.1 3.53i0.2aa
CP 2.5010.1 2.2810.21 2.3910.1 2.5210.3
GLYCOGEN 11.8810.3 10.6310.93 4.7110.4** 5.0810.5**
cc-GP 0.6810.1 1.5210. laa 0.1510.2** 0.58i0.05aa
GLYCEROL 0.3210.1 0.0010.0 0.6010.1 0.4010.1
TAG 0.50 (0.2,1.9) 0.50 (0.2,2.2) 0.40 (0.3,1.4) 0.40 (0.3,1.3)
Metabolite concentrations are expressed as (imol.g'^wet wt. (MeaniSEM),except TAG
concentrations which are expressed as Median (95% Confidence limits).
Glycogen concentration is expressed as glucose equivalents.
** PcO.Ol vs CONTROL (t-test); aa PcO.Ol vs Normoxia (t-test)
Hearts from obese rats exhibited elevated CP concentrations compared with control rat
hearts after both normoxia and hypoxia (Table 4.5). The TAG concentrations in hearts
from obese rats were significantly higher than in the control group after both normoxic
and hypoxic perfusion. Glycogen concentrations were also raised in obese rat hearts
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after normoxic perfusion but were not different than in hearts from the control group
after hypoxia (Table 4.5).
Table 4.5. The influence of normoxic and hypoxic perfusion on metabolite
concentrations in hearts from control and fed rats.
CONTROL OBESE
Normoxia Hypoxia Normoxia Hypoxia
ATP 4.1310.2 2.9910.2 4.3710.1 3.5510.1
CP 2.5610.1 2.2810.2 3.3510.2* 3.2210.1*
GLYCOGEN 11.8811.3 10.6310.9 14.8411.9* 12.5611.1
a-GP 0.6810.1 1.5210.1 0.2610.04 0.7310.1
GLYCEROL 0.3210.1 0.0010.1 0.2710.1 0.3110.31
TAG 0.50 (0.2,1.9) 0.5 (0.2,2.2) 8.5 9.0
(6.5,12.4)** (5.9,13.2)**
Metabolite concentrations are expressed as pmol.g'^wet wt. (Mean±SEM), except TAG
concentrations which are expressed as Median (95% Confidence limits).
Glycogen concentration is expressed as glucose equivalents.
a-GP = a-glycerophosphate.
* P<0.05 vs CONTROL (t-test).
** P<0.01 vs CONTROL (t-test).
aa P<0.01 vs Normoxia (t-test).
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(For the sake of clarity the data from the control group is presented in Tables 4.3,4.4 and
4.5).
The pattern of glycerol release from hearts from obese rats during hypoxia differed
from that seen with hearts from the control group (Fig 4.3).
Figure 4.3. The influence of obesity on hypoxia-stimulated glycerol release from the
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Glycerol release is expressed as nmol.g'l wet wtmin"* (Mean±SEM).
*P<0.05 vs LEAN (t-test)
**P<0.01 vs LEAN (t-test)
Glycerol production from obese rat hearts was increased during the first 30 min
(normoxic) perfusion, after which, in the normoxic group glycerol efflux decreased and
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was not significantly different than in control rat hearts. When hypoxia was induced,
glycerol efflux from hearts from obese rats gradually increased during the first 15 min,
after which glycerol production began to decline. After 30 min hypoxia, the rate of
glycerol release from control hearts was significantly higher than from obese rat hearts.
Glycerol release from obese-rat hearts was more variable than from hearts in the control
group (Standard deviation = 13 pmol.g~1.30min~l lean vs 143 |imol.g"1.30min"l obese).
Unlike glycerol, lactate production from hearts from obese rats showed a similar
pattern to lactate production from hearts in the control group.
The amount of ATP utilized in TAG-NEFA cycling was calculated as described in
Section 3.4. The results are as shown in Table 4.6.
Table 4.6. ATP production, and utilization in TAG-NEFA cycling during hypoxia in
hearts from different types of rat.
Type of rat ATP production ATP used for % ATP used
TAG-NEFA
Aerobic Anaerobic cycling
Control 428.4±7.2 137.1±21.6 5.3810.4 0.9510.03
Young 421.2±7.2 64.5117.4 3.6310.3 0.7510.03
Fasted 455.4±9.0 85.2115.6 1.9610.2 0.3610.03
Obese 428.4±9.0 67.0114.9 5.0410.6 1.0210.03
ATP production and utilization is expressed as |imol.g~1.30min~l (MeaniSEM).
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4.4. Discussion
The results from this study demonstrate that increased myocardial TAG concentrations
in the obese rat do not have a significant effect on the total amount of glycerol released
from the isolated, perfused rat heart during a 30 min period of hypoxia
(30%02/65%N2/5%C02). However, the relationship of glycerol release with time was
somewhat anomalous in this group. The proportion of total ATP production utilized in
TAG-NEFA cycling was slightly increased in hearts with raised TAG concentrations i.e.
hearts from obese rats, but this increase was associated with decreased anaerobic ATP
production during hypoxia compared with hearts from lean rats, rather than increased
lipolysis. Even when glycerol release from the obese rat hearts was at its maximum i.e.
after 15 min hypoxia (Figure 4.3.), it can be calculated that only 1.5% of the ATP
produced would be utilized for TAG-NEFA cycling. Furthermore, the increase in TAG-
NEFA cycling in hearts from obese rats had no effect on high energy phosphate
concentrations in the heart. On the contrary, CP levels were higher in hearts from obese
rats than in hearts from lean rats after hypoxia.
Obviously, obesity is a pathological condition and results from these hearts may be
complicated by factors such as changes in membrane structure and response to stimuli.
However, as the hearts were removed from the animals and subjected to the same
environment as the normal hearts, many of the complicating factors present in vivo are
removed. The high variation in glycerol release from obese rat hearts during hypoxia
compared with that in hearts from the control group may be due to variation in the
number of adipocytes present in hearts from obese rats. It has been reported that few
adipocytes are present in hearts from lean rats (Denton and Randle 1967).
Obesity is known to be accompanied by insulin resistance (Girolamo and Rudmen
1966). This would be expected to lead to decreased glucose uptake in hearts from obese
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rats. Although insulin was not present in the perfusate during the experiment, the effects
of insulin are known to remain for up to 30 min after commencing perfusion (Fisher and
O'Brien 1972). After the preperfusion period, cannulation of the pulmonary artery takes
approximately 5 min. Thus the first coronary effluent sample was collected after 30 min
perfusion. Differences in metabolism due to the effects of endogenous insulin are
therefore unlikely to be present during the experiment.
The lower lactate production and apparent decreased glycogen utilization during
normoxia in hearts from obese rats compared with hearts from lean rats suggests
decreased glycolytic flux in obese-rat hearts. This may be due to increased fatty acid
oxidation, causing inhibition of phosphofructokinase by increased citrate and ATP
production, and therefore a reduction in the rate of glycolysis. However, if glycerol
production were to reflect TAG breakdown, and this could consequently be extrapolated
to represent fatty acid oxidation during normoxia, no significant difference in fatty acid
oxidation is apparent between hearts from lean and obese rats. Fatty acids may also be
incorporated into the phospholipid pool, meaning that glycerol release would be an over-
estimation of fatty acid oxidation. The amount of fatty acid oxidation could not be
assessed due to the difficulty in obtaining accurate RQ values for this model as explained
in Section 2.4.
The pattern of glycerol release from obese-rat hearts during hypoxia is unusual; in all
other groups of hearts glycerol efflux showed no decline as the duration of hypoxia
increased. Lipolysis in the heart has been related to mechanical activity (Stam and
Hulsmann 1981). It is possible that the decline in glycerol efflux from hearts from
obese rats during the later stages of hypoxia may reflect a concurrent decline in
mechanical activity.
Lipolysis, assessed as glycerol release, is increased in hearts from rats in which
myocardial TAG concentrations were raised by feeding on a high fat diet (Brownsey and
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Brunt 1977, Stam and Hulsmann 1981a). In the obese rat, despite raised levels of TAG
in the heart, the total amount of glycerol released was not different than that from lean-
rat hearts. The existence of different TAG pools with varying turnover rates has been
suggested (Stein and Stein 1968, Wood et al. 1972, De Groot et al. 1989). In the obese-
rat heart, myocardial TAG stores may be less metabolically available, so that TAG
accumulates in the heart but cannot be fully utilized for energy production.
Alternatively, if adipocytes react differently to hypoxia than do myocytes, a significant
contribution of adipocytes in hearts from obese rats would explain the different metabolic
profiles of the control and obese groups.
The effect of fasting on myocardial TAG concentration has been controversial.
Several groups have reported increased TAG levels in rat hearts after fasting for 48 h
(W ittels and Bressler 1964, Denton and Randle 1967, Lascano et al. 1981). All of
these studies included MAG (monoacylglycerol) and DAG (diacylglycerol) in
measurement of TAG concentrations and therefore probably overestimated TAG levels.
However, concentrations of MAG and DAG in the heart are thought to account for less
than 10% of the total glyceride concentration (Denton and Randle 1967). Their inclusion
in TAG measurements is therefore unlikely to make a difference in the overall
conclusion of an experiment, particularly as MAG and DAG were included in
measurement of glyceride levels both before and after fasting. Other groups have
reported decreased TAG levels in rat heart after fasting (Gorski and Kiryluk 1981, Arnall
et al. 1988). This is surprising since myocardial TAG concentrations have been reported
to be proportional to circulating NEFA concentrations (Paulson and Crass 1982) and
plasma NEFA are known to be raised during fasting (Denton and Randle 1967). It
should also be pointed out that due to the large variation of myocardial TAG levels
within groups it is difficult to demonstrate a small difference between groups without the
use of very large group sizes.
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Sympathetic nervous system activity, demonstrated by noradrenaline turnover in the
isolated, perfused rat heart, is suppressed during fasting, and this may be reversed by
feeding (Landsberg and Young 1982). In addition, Brooks et al. (1983) demonstrated an
increase in TAG-NEFA cycling in adipose tissue during feeding and attributed this to
increased sympathetic nervous system activity and raised local concentrations of
noradrenaline, due to the fact that feeding failed to increase the rate of cycling after
injection of the P-blocker propranolol.
If the increase in glycerol and lactate release observed during hypoxia are the result of
endogenous catecholamine release, diminished local concentrations of catecholamines in
the heart during fasting could explain the decreased glycerol and lactate production from
fasted-rat hearts during hypoxia compared with hearts from fed rats.
The age difference between the young and control rats used in this study was probably
too small to show major differences in myocardial TAG concentrations. Hearts from rats
younger than those used in this study would not be suitable for use in these experiments
due to their small size and therefore difficulty in cannulation. Previous studies
demonstrating differences in TAG metabolism have compared rats of 12 weeks with 1
et ail-
year old rats (Reaver^978). The increased ATP concentrations in heart tissue from
young rats after normoxia implies more efficient energy utilization in heart from young
rats than in hearts from old rats. This could be explained by decreased ATP utilization
for re-esterification of NEFA in hearts from young rats, as the decreased glycerol release
during hypoxia implies a lower rate of TAG-NEFA cycling.
In summary, the changes in metabolism induced by age, fasting and obesity had little
effect on the rate of TAG-NEFA cycling. The results suggest that the hypothesis that
TAG-NEFA cycling becomes more important as a cause of energy wastage during
oxygen deprivation when TAG levels are raised should be rejected. However, this study
has compared the effects of metabolite concentrations only during normoxia and
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relatively mild hypoxia. The influence of alterations in metabolite concentrations on the
cycling rate during severe hypoxia and ischaemia remains to be studied.
If the responses observed in hearts from fasted rats are indeed the result of increased
sympathetic nervous system activity, the findings of this study suggest that
catecholamine release during hypoxia may be more important in determining
biochemical changes during oxygen deprivation than levels of endogenous substrates.
The involvement of endogenous catecholamines in the metabolic response to hypoxia is
examined in the following chapter.
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CHAPTER 5
THE INVOLVEMENT OF ENDOGENOUS CATECHOLAMINE
RELEASE IN HYPOXIA-STIMULATED GLYCEROL RELEASE




Alterations in myocardial metabolism are centrally involved in the development of
arrhythmias. It is therefore important to understand the mechanisms controlling these
changes during oxygen deprivation.
Hypoxia is thought to stimulate release of endogenous catecholamines in the heart
(Wollenberger and Shahab 1965, Karwatowska-Krynska and Beresewicz 1983). These
hormones bind to (3- adrenoceptors on cell membranes and thus increase the activity of
the enzyme adenylate cyclase. Adenylate cyclase catalyzes conversion of intracellular
ATP to the second messenger cAMP. cAMP in turn activates protein kinases in the
cytoplasm. These enzymes then phosphorylate other regulatory enzymes, either
activating or deactivating them (Fig 5.1).
Catecholamine-mediated increases in cAMP concentrations in the myocardium have
been linked to the ocurrence of ventricular arrhythmias (Corr et al. 1978, Opie et al.
1979). Podzuweit et al. (1980) suggested that an increase in cAMP in the ischaemic heart
may precede and cause ventricular fibrillation. In agreement with this theory, agents
which increase intracellular levels of cAMP, such as inhibitors of phosphodiesterase (the
enzyme which breaks down cAMP), are known to increase the severity of ischaemic
arrhythmias (Kane et al. 1985). In the in vitro, coronary-artery-ligated rat heart,
administration of the synthetic catecholamine analogue isoprenaline increased both
cAMP levels and the incidence of ventricular fibrillation (Manning et al. 1985). Other
groups have demonstrated a decreased incidence of arrhythmias in hearts depleted of
endogenous catecholamines (Sethi et al. 1973, Sheridan et al. 1980). It is not known
which of the biochemical changes induced by cAMP are arrhythmogenic.
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Furthermore, the involvement of cAMP in the generation of arrhythmias has been
questioned. Coronary occlusion-induced arrhythmias in the anaesthetized rat were not
accompanied by temporally related increases in cAMP, although an unsustained increase
in cAMP during early ischaemia was observed (Kane et al. 1985). Also, during global
ischaemia in the rat heart, the activity of adenylate cyclase was significantly reduced
compared with that in normal myocardium (Krause and England 1982, Reddy 1989).
The role of catecholamine- mediated responses in the genesis of arrhythmias is therefore
unclear.
A TAG lipase in the heart may be be activated by P-adrenoceptor stimulation
(Christian et al. 1968, Brownsey and Brunt 1977, Hough and Gevers 1975).
Catecholamine-stimulated glycerol release from the isolated, perfused rat heart is
preceded by an increase in cAMP (Christian et al. 1968). In addition, hormone-
stimulated glycerol release in the heart is accompanied by an increase in the protein
kinase ratio (Jesmok et al. 1977, Hron et al. 1977). Glycerol release was not increased
during ischaemia in isolated, perfused hearts from animals denervated by pretreatment
with reserpine (Hough and Gevers 1975) or hypoxia (Karwatowska-Krynska and
Beresewicz 1983).
P adrenoceptor blocking agents such as atenolol (a selective pj receptor blocker) and
timolol (a non-selective P-blocker) are well known to have antiarrhythmic properties
(Campbell et al. 1982, Patterson et al. 1984, Sleight 1988). These drugs act as
competitive antagonists by binding to P receptors and therefore preventing the binding of
P receptor agonists such as the endogenous catecholamine noradrenaline or the synthetic
catecholamine analogue isoprenaline.
The aim of this study was to assess the role and possible importance of endogenous
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catecholamine release in the metabolic changes induced by hypoxia with the use of (3-
adrenoceptor agonists and antagonists.
Ill
5.2. Methods.
Hearts from male Sprague Dawley rats (body weight 400-450g) were removed and
perfused as described in section 2.1.2.
The basic protocol consisted of a 60 min period of perfusion. An initial period (30
min) acted as a control for the second (experimental) period.
5.2.1. Noradrenaline release during normoxia and hypoxia.
The conditions used for the experiments were as shown in Table 5.1.
Table 5.1. Experiment 1: Conditions used to study the role of noradrenaline release












Coronary effluent was collected at 5 min intervals. Samples collected at
t=5,15,25,35,45 and 55 min were analyzed for catecholamines. Samples for
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catecholamine analysis were also collected from two hearts from each group for at 1
minute intervals from t=30 to t=40 min. Samples collected at t=10,20, 30,40, 50 and
60 min were analyzed for glycerol and lactate.
5.2.2. The influence of exogenous catecholamines and their antagonists on metabolic
changes during normoxia and hypoxia.
The second series of experiments set out to examine the role of the (3-adrenoceptor
agonist isoprenaline and antagonists atenolol and timolol on myocardial glycerol release
during normoxia and hypoxia. The conditions used are shown in Table 5.2.
Table 5.2. Experiment 2: The conditions used to study the influence of exogenous
catecholamines and their antagonists on metabolic changes during normoxia and
hypoxia.
Group No. of hearts Conditions
E 6 Normoxia + Isoprenaline
F 6 Normoxia + Isoprenaline + Atenolol
G 6 Hypoxia + Atenolol
H 8 Severe hypoxia
I 4 Severe hypoxia + Atenolol
J 6 Hypoxia + Isoprenaline
K 6 Hypoxia + Isoprenaline + Atenolol
L 3 Isoprenaline + Timolol
M 6 Hypoxia + Timolol
Normoxia = 95%C>2/5%C02 (PO2 600±6 mmHg)
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Hypoxia = 30%02/65%N2/5%CO2 (P02 220±6)
Severe hypoxia = 10%02/85%N2/5%C02 (P02 58±8)
All drugs were infused proximal to the heart at a rate of 0. lml/min. Atenolol and
timolol were infused from t=0 to t=60 min; Isoprenaline was infused from t=31 to t=60
min.




Coronary effluent was collected at 10 min intervals (from t=10 to t=60 min) and
analyzed for glycerol and lactate. At t=60 min hearts were freeze-clamped, ffeeze-dried
and the tissues analyzed for ATP, CP, glycogen, a-glycerophosphate, glycerol and TAG
as described in Chapter 2.
5.2.3. Experiment 3: The effect of denervation on metabolic changes during
normoxia and hypoxia.
Rats received intraperitoneal injections of 6- hydroxydopamine-HBr (dissolved in
sterile saline containing ascorbic acid (1%)) as follows:
Days 1 and 2 50 mg/kg
Days 8 and 9 100 mg/kg
The effects of chronic denervation on hypoxia- induced changes in metabolism was
studied 10 days after the final dose was administered (Day 19).
Two sub groups were treated as follows:
Group I (n=6) - Hearts were removed, perfused for a few seconds in order to wash out
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blood and then freeze- clamped. This group was used to examine the effects of
pretreatment with the drug before perfusion.
Group II (n=6) - Hearts were removed, perfused normoxically for 30 min followed by
30 min hypoxia (30%C>2/ 65%N2/5%CC>2). Coronary effluent was collected at 10 min
intervals from t=10 to t=60 min. At t=60 min hearts were freeze-clamped.
All hearts from 6-hydroxydopamine treated rats were freeze-dried and analyzed for
catecholamines, ATP, CP, glycogen, a-glycerophosphate, and TAG as described in
Chapter 2.
Oxygen uptake was monitored throughout all experiments.
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5.3 Results.
5.3.1. Noradrenaline release during normoxia and hypoxia.
A period of 30 min hypoxia did not induce noradrenaline release from the isolated,
perfused rat heart, irrespective of the severity of the hypoxic insult. On the other hand,
hypoxia-stimulated glycerol and lactate release as described in Chapter 3 were evident
(Glycerol release 902±86 nmol.g'l per 30 min, lactate release 144±14 (imol.g'l per 30
min; Mean±SEM, P<0.01 vs normoxia). There was no change in catecholamine release
in any of the groups after induction of hypoxia (Table 5.3).
Table 5.3. Noradrenaline concentration in coronary effluent (nM) during normoxia
and varying severities of hypoxia.
Group A B C D
% OXYGEN 95 30 20 10
No. of hearts 8 6 6 6
5 min 0.53±0.2 0.2910.1 0.2010.03 0.14i0.1a
15 min 0.4010.1 0.31i0.05ac 0.17i0.03a 0.0710. la
25 min 0.4110.1 0.32i0.03a 0.10i0.02a 0.0610. la
HYPOXIA
35 min 0.3910.1 0.2810.03 0.14i0.04ab 0.0710. la
45 min 0.3810.1 0.3810.1 0.12i0.04a 0.1610.1
55 min 0.3210.1 0.2910.03 0.1910.1 0.1310.1
a P<0.05 vs Group A; b P<0.05 vs Group B; c P<0.05 vs Group C
Results are expressed as MeaniSEM.
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Some differences in noradrenaline concentration in the coronary effluent were evident
between groups during both normoxia and hypoxia. However, even in the groups in
which noradrenaline release was raised compared with the other groups, the levels
measured were much lower than the levels previously reported during anoxia (26 nM;
Karwatowska-Krynska and Beresewicz 1983). Noradrenaline release from all groups of
hearts remained constant during the first 10 min of hypoxia.
5.3.2. The influence of exogenous catecholamines and their antagonists on metabolic
changes during normoxia and hypoxia.
5.3.2.(a) Isoprenaline
Glycerol release was readily stimulated in the normoxic heart by infusion of
isoprenaline (lOnM) (Fig 5.2). The amount of glycerol released during a 30 min period
of infusion of the drug (952±175 nmol) was similar to the amount released during a 30
min period of hypoxia (30%O2/65%N2/5%CC>2) (8971119 nmol; MeanlSEM).
Lactate production was also stimulated during isoprenaline infusion but no significant
effect on oxygen uptake could be found (Table 5.4).
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Figure 5.2. The influence of isoprenaline (10 nM) on glycerol release from the





Glycerol release is expressed as nmol.g wet wt.'^min'^ (MeanfSEM).
0 1 0 20 30 40 50
TIME (min)
Tisue glycogen concentrations were significantly lower and CP concentrations
significantly higher after isoprenaline infusion (Table 5.5). Tissue a- glycerophosphate
concentration was not affected by isoprenaline. Despite the increase in glycerol release
during infusion of isoprenaline, myocardial TAG levels remained unchanged.
Therefore, if glycerol release may be used as a measure of TAG breakdown, the results
indicate that TAG-NEFA cycling is stimulated by exogenous catecholamines.
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Table 5.4. The influence of exogenous catecholamines and their antagonists on
glycerol (nmol.g-1 per 30 min) and lactate ((imol.g'l per 30 min) release and oxygen
uptake (pmol.g"lmin"l) during normoxia.
Glycerol release Lactate release Oxygen uptake






Isoprenaline + 194±46aa 55118^ 4.411.4^
Timolol
Results are expressed as MeanlSEM.
** P<0.01 vs Normoxic control
aa P<0.01 vs Isoprenaline
5.3.2.(b) Isoprenaline and Atenolol.
As expected, isoprenaline-stimulated glycerol release was inhibited by the (3-
adrenoceptor blocking agent atenolol (Table 5.4). However, isoprenaline- stimulated
lactate release was only partially blocked when atenolol was infused (Table 5.4). The
decrease in tissue glycogen concentration observed after isoprenaline infusion was
prevented by atenolol (Table 5.6).
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5.3.2.(c) Hypoxia and Atenolol.
In contrast to the effect of atenolol on isoprenaline-induced glycerol release, the (3-
blocker failed to prevent hypoxia-stimulated glycerol release (Table 5.5). Hypoxia-
stimulated lactate release was also unaffected. However, the drug prevented the hypoxia
induced decrease in ATP and significantly attenuated the increase in tissue a-
glycerophosphate concentration observed after hypoxia (Table 5.6). Atenolol had no
effect on oxygen uptake during hypoxia (Table 5.5).
Table 5.5. The influence of exogenous catecholamines and their antagonists on
glycerol (nmol.g"! per 30 min) and lactate (|imol.g"l per 30 min) release and oxygen
uptake (pmol.g"lmin"l) during hypoxia.
Glycerol Lactate Oxygen
release release uptake
Hypoxia 8971119 133112 2.410.04

























Results are expressed as Mean±SEM.
aa P<0.01 vs Isoprenaline (Table 5.4)
b P<0.05 vs Hypoxic control
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Glycerol and lactate release were significantly higher, and oxygen uptake significantly
lower than the normoxic control values (Table 5.4; PcO.Ol, not indicated).
5.3.2.(d) Severe hypoxia and atenolol.
Glycerol and lactate release during severe hypoxia were also unchanged when atenolol
was infused (Table 5.5). The decrease in ATP and CP observed during severe hypoxia
was attenuated in the presence of atenolol. However, ATP and CP concentrations were
lower than in normoxically perfused, untreated hearts. The increase in tissue a-
glycerophosphate concentration observed during severe hypoxia was prevented by
atenolol (Table 5.6).
5.3.2.(e) Hypoxia and Isoprenaline.
^-adrenoceptors remained sensitive to isoprenaline during hypoxia, demonstrated by an
increase in glycerol release from 8971317 nmol per 30 min (hypoxia) to 17711307 nmol
per 30 min (hypoxia and isoprenaline) (P<0.05; Table 5.5). ATP, glycogen and a-
glycerophosphate concentrations in the heart tissue were significantly lower than in
normoxically perfused, untreated hearts. Glycogen and a-glycerophosphate
concentrations were significantly lower than after hypoxia alone but not significantly
different than with isoprenaline alone (Table 5.6). Oxygen uptake was not significantly
different than during hypoxia alone (Table 5.5).
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5.3.2.(f) Hypoxia, Isoprenaline and Atenolol.
Atenolol prevented the isoprenaline-induced increase in glycerol release during
hypoxia. When isoprenaline and atenolol were infused simultaneously during hypoxia,
both glycogen and a-glycerophosphate concentrations in the heart were significantly
higher than when atenolol was omitted (Table 5.6). The tissue a-glycerophosphate
concentration was significantly lower than after hypoxia alone but significantly higher
than in normoxically perfused, untreated hearts. The tissue ATP concentration was
significantly lower than in normoxic, untreated hearts but not significantly different than
with hypoxia alone or isoprenaline alone (Table 5.6). Atenolol had no effect on oxygen
uptake in this group of hearts (Table 5.5).
5.3.2.(g) Isoprenaline and Timolol.
The non-selective P-adrenoceptor blocking agent timolol inhibited isoprenaline-
stimulated glycerol and lactate release (Table 5.4). ATP concentrations in heart tissue
were significantly higher when timolol and isoprenaline were infused simultaneously
than when isoprenaline was infused alone. However, ATP concentrations after timolol
infusion were not significantly different than in normoxic, untreated hearts (Table 5.6).
Tissue a-glycerophosphate concentrations were significantly lower in the presence of
timolol and isoprenaline compared with when isoprenaline was infused alone (Table 5.6).
Oxygen uptake during isoprenaline and timolol infusion was significantly lower than
during isoprenaline infusion alone, but not significantly different than in normoxic,
untreated hearts (Table 5.4).
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5.3.2.(h) Hypoxia and Timolol.
Timolol had no effect on glycerol or lactate release during hypoxia (Table 5.5). CP
and glycogen concentrations in heart tissue were significantly higher when timolol was
infused during hypoxia. Glycogen concentrations were significantly higher than in
normoxic, untreated hearts. Tissue a- glycerophosphate concentrations were
significantly lower when timolol was infused during hypoxia (Table 5.6).
5.3.3. The effect of denervation on metabolic changes during hypoxia.
Glycerol (Fig 5.3) and lactate release were stimulated during hypoxia in hearts from 6-
hydroxydopamine treated rats.
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Figure 5.3. The influence of pretreatment with 6-hydroxydopamine on hypoxia




Glycerol release is expressed as nmol.g'^wet wt. min'l (Mean±SEM).
* P<0.05 vs CONTROL
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However, the total glycerol and lactate production was significantly lower than that
from untreated rat-hearts (Table 5.7).
Table 5.7. The influence of 6-hydroxydopamine pretreatment on glycerol and
lactate release during hypoxia (30 min).
Glycerol release Lactate release
(nmol.g'^wet wt.) (p.mol.g"^wet wt.)
Hypoxic control 896.9±129 132.5±7
6-Hydroxydopamine 628.9±72** 95.3±14**
treated
Results are expressed as Mean±SEM.
** P<0.01 vs Hypoxic control
ATP, CP and a-glycerophosphate concentrations in hearts from rats pretreated with 6-
hydroxydopamine were significantly lower than in hearts from normal rats before
perfusion (Table 5.8). Glycogen and TAG concentrations were not affected by
treatment with 6- hydroxydopamine.
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Table 5.8. Effects of pretreatment with 6-hydroxydopamine on myocardial








TAG 1.81 (1.7,2.5) 2.52 (1.9,3.7)
Results are expressed as Mean±SEM, except TAG concentrations which are expressed as
Median (95% Confidence limits).
* P<0.05 vs Control
** PcO.Ol vs Control
After 30 min hypoxia there was no difference in metabolite concentrations in hearts
from 6- hydroxydopamine treated and untreated rats (Table 5.9).
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Table 5.9. The effects of pretreatment with 6-hydroxydopamine on myocardial
metabolite concentrations (pmol.g'^wet wt.) in the isolated, perfused rat heart after







TAG 0.50 (0.2,2.2) 0.72 (0.2,2.2)
NS = Not significant.
Results are expressed as MeaniSEM, except TAG concentrations which are expressed as
Median (95% Confidence limits).
Oxygen uptake in hearts from treated rats was not significantly different than in hearts
from untreated rats.
Myocardial noradrenaline concentrations after treatment with 6-hydroxydopamine were
0.02±0.02 nmol.g" *wet wt. (Mean±SEM). These levels are less than 1% of normal
myocardial noradrenaline levels (~ 8 nmol.g" * wet wt; Abrahamsson et al. 1982).
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5.4. Discussion
Myocardial catecholamine release could not be demonstrated during hypoxia, even
when the severity of hypoxia was increased. The effects of hypoxia on catecholamine
release have not been studied previously. However, several groups have examined the
effects of anoxia. The results presented here agree with those of Dart et al. (1987) and
Schomig et al. (1987), but contradict those of Karwatowska-Krynska and Beresewicz
(1983) who reported a significant increase in noradrenaline release, accompanied by a
large increase in glycerol release from isolated, perfused rabbit hearts during the first 5 to
10 min of anoxia. It is possible that the discrepancies in results simply reflect species
differences, but no systematic study of this appears to have been made. Another
possibility is that the latter study used a constant pressure rather than a constant flow
perfusion system. Consequently large increases in flow rates were recorded on
induction of anoxia. Reuptake of endogenous catecholamines may therefore have been
limited due to high flow rates and subsequent increased washout (Dart and Riemersma
1985). The large amount of glycerol produced by rabbit hearts during anoxia
(95%N2/5%CC>2) (~22000 nmol.g'^min" Karwartowska-Krynska and Beresewicz
1983) compared with that released from rat hearts during severe hypoxia
(10%C>2/85%N2/5%CC)2) (99 nmol.g'lmin'l) may reflect a higher proportion of
adipocytes in rabbit heart than in rat heart, but data to confirm or deny this does not
appear to be available. The pattern of glycerol release from the rabbit heart during
anoxia was different from that observed in the hypoxic rat heart, in that glycerol efflux
rapidly increased during the first five minutes of anoxia and then decreased, reaching
levels not different than those observed in the normoxic heart after 30 min. In the rat
heart, glycerol release continued to increase over a 30 min period of hypoxia (see Fig
5.3). Wollenberger and Shahab (1965) also reported anoxia-stimulated noradrenaline
release from the rabbit heart. However, this was only recorded on reoxygenation of the
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tissue. The report does not state whether a constant flow or constant pressure perfusion
system was used.
The stimulation of lipolysis by exogenous catecholamines in the normoxically perfused
heart, resulting in increased glycerol efflux has been well documented (Challoner and
Steinberg 1965, Christian et al. 1968, Jesmok et al 1977, Stam and Hulsmann 1981a).
Infusion of isoprenaline (lOnM) resulted in glycerol release similar to the amount
released during hypoxia (30%O2/65%N2/59%CC>2). As expected, isoprenaline-
stimulated glycerol release was readily inhibited by the Pi-adrenoceptor antagonist
atenolol. Isoprenaline-stimulated lactate release was only partially inhibited by atenolol,
but almost completely inhibited by timolol, implying that both Pi and p2-adrenoceptors
may be involved in this process.
These observations are in sharp contrast to the failure of atenolol to block glycerol
release during hypoxia, suggesting that hypoxia-stimulated glycerol efflux is not a result
of endogenous catecholamine release. However, atenolol did reduce the hypoxia-
stimulated decrease in ATP and prevented the decrease in tissue glycogen concentration
observed during severe hypoxia, suggesting that some endogenous catecholamines are
released and that their effects may be prevented by a Pi-adrenoceptor antagonist. The
effects of the P-blocker on metabolism during hypoxia could also be a consequence of
the infusion of the drug during the 30 min normoxic period prior to hypoxia, and hence
inhibition of the actions of basal catecholamine release.
Isoprenaline-induced glycerol release was not significantly different during normoxia
and hypoxia, suggesting that hypoxia neither impairs P- adrenoceptor function, nor
affects the efficacy of the P-adrenoceptor blocking agents. Isoprenaline- stimulated
glycerol release from isolated myocytes was attenuated during anoxia (95%N2/5%CC>2)
compared with during normoxia (Larsen et al 1989). This apparent disparity between
results may reflect a difference between total oxygen deprivation (anoxia) and a
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reduction in oxygen supply (hypoxia). Also, with the use of isolated myocytes, isolation
of the cells per se may modify the response of receptors to anoxia. On the other hand,
other cell types such as adipocytes are removed from isolated myocyte preparations and
results therefore reflect purely myocyte metabolism. Thus it may be that the sensitivity
of myocyte P- adrenoceptor function to oxygen deprivation in the isolated heart is
masked by the response of adipocytes to isoprenaline. Adipocytes require much less
energy than do myocytes due to their lack of mechanical activity and would therefore be
expected to be less sensitive to hypoxia.
Atenolol is a selective Pi-adrenoceptor antagonist. The lipolytic effects of P-receptor
stimulation are thought to be mediated via Pj- adrenoceptors (Arnold et al. 1966).
Cardiac tissue has been reported to contain a significant proportion of P2-adrenoceptors
(Jones et al. 1989), although this varies between species (rat heart tissue contains mainly
the Pi subtype). The effect of the non- selective P-adrenoceptor antagonist timolol was
studied to eliminate the possibility that glycerol efflux during hypoxia was a result of P2-
adrenoceptor stimulation. The results suggest that hypoxia-stimulated glycerol release
does not involve P2-adrenoceptor stimulation.
Although the concentration of the P-adrenoceptor blocking agents used in this study
was relatively high, it is possible that the action of endogenous catecholamines may not
have been completely inhibited. 6-Hydroxydopamine causes selective degeneration of the
terminal part of adrenergic neurons resulting in long- lasting depletion of endogenous
et <U •
catecholamines and functional sympathectomy (Haeuslerj(1969). Pretreatment of rats with
this drug should remove any catecholamine mediated responses observed during hypoxia.
Pretreatment of rats with 6-hydroxydopamine did not prevent stimulation of glycerol
release during hypoxia. However, the total amount of glycerol released during the 30 min
period of hypoxia was significantly lower than in hearts from untreated rats. Assuming
that the decrease in hypoxia-stimulated glycerol release in pretreated rats represents
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catecholamine-mediated glycerol release, it can be calculated that approximately 30% of
the glycerol and 28% of the lactate released during hypoxia is the result of endogenous
catecholamine release. This implies that infusion of (J-adrenoceptor antagonists is
inadequate in inhibiting endogenous catecholamine-mediated responses.
6-Hydroxydopamine pretreatment prevented the hypoxia-induced decrease in ATP,
suggesting that the decline in ATP levels during hypoxia is catecholamine- mediated.
However, the fact that high energy phosphate levels were lower in hearts from 6-
hydroxydopamine pretreated rats than in hearts from control rats suggests that under
normoxic conditions catecholamines may play a role in maintaining high energy
phosphate levels in the heart. The increase in tissue CP concentration observed during
isoprenaline infusion in the normoxic heart supports this argument.
Catecholamines are well known to cause an inotropic response which would be likely
to increase energy utilization in the heart. The changes in metabolism observed during
isoprenaline infusion may therefore be partly due to alterations in mechanical activity as
well as biochemical changes. However, even if the heart rate is controlled, the work
done by the heart cannot be easily monitored (Elzinga 1983). Also high energy
phosphate levels are maintained with a 4 to 5 fold increase in heart rate (Kammermeir et
al. 1990). Hypoxia-stimulated glycerol release has previously been attributed to the
action of a hormone-sensitive lipase (Christian et al. 1968, Hough and Gevers 1975,
Karwatowska-Krynska and Beresewicz 1983). These results demonstrate that the
majority of the hypoxia- stimulated glycerol release was the result of non- adrenergic
mechanisms. Non hormone-stimulated glycerol release must be the consequence either
of activity of a lipase which is activated during hypoxia independent of endogenous
catecholamines, or breakdown of a-glycerophosphate or phospholipids rather than TAG.
The presence of both a lysosomal and a soluble fraction acid lipase with significant
activity towards a-glycerophosphate has been demonstrated in rat liver (Shibfco and
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Tappel 1962), and a similar acid phosphatase is known to be present in rat ventricle
(Welman and Peters 1976). Activity of lysosomal enzymes increases during anoxia
(Welman 1974). It is possible that increased acid phosphatase activity in the heart during
hypoxia may lead to increased glycerol release via a-glycerophosphate breakdown,
although this needs to be further investigated.
Additionally, phospholipid breakdown may result in glycerol efflux during hypoxia.
The content of myocardial phospholipids does not change significantly within 1 hour of
ischaemia (Chien et al. 1984, Das et al. 1986, van der Vusse et al. 1987). However, a
very small change in the phospholipid pool could conceivably result in a significant
amount of glycerol release (van der Vusse et al. 1987). Since arachidonic acid is a fatty
acid found almost entirely in phospholipid, increases in intracellular arachidonate levels
are thought to provide evidence for increased phospholipase A2 activity. The
accumulation of unesterified arachidonate is minimal during 10-30 min of ischaemia in
canine left ventricle and does not increase significantly until after 1-3 hours of ischaemia
(Chien et al. 1984). However, deacylation and reacylation of phosphatidylcholine is
thought to occur under normoxic conditions and during the early stages of myocardial
ischaemia. This could lead to glycerol release from the heart. Changes in phospholipid
metabolism during hypoxia have not been reported. However, addition of phospholipase
C to isolated myoctes stimulates glycerol release during anoxia, but not during normoxia
(Myrmel et al. 1989).
In conclusion, the results from this study show that approximately 30% of the glycerol
release from the heart during hypoxia is due to myocardial lipolysis stimulated by
endogenous catecholamines. More experiments are needed to determine the mechanisms
involved in stimulating the remainder of the glycerol efflux during hypoxia and also the
origin of the glycerol released from the heart during oxygen deprivation.
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CHAPTER 6
THE ORIGIN OF GLYCEROL RELEASE




It is generally assumed that glycerol release during hypoxia is the result of hormone-
stimulated lipolysis (Christian et al. 1968, Jesmok et al. 1977). A large proportion of
glycerol released from the isolated, perfused rat heart during hypoxia is the result of non-
adrenergic mechanisms). Hypoxia-stimulated glycerol release must therefore be either
the result of a TAG lipase activated during hypoxia independent of catecholamines, or
originate from a source other than TAG (ie. either a-glycerophosphate or phospholipids).
The common use of glycerol release as an index of lipolysis is thus brought into question
(Chapter 5).
Breakdown of a-glycerophosphate by acid phosphatase could lead to glycerol
production. The possible contribution of acid phosphatase to glycerol release during
hypoxia therefore needs to be investigated, particularly since there is a positive
correlation between myocardial a-glycerophosphate concentration and glycerol release
over a range of conditions (Fig 6.1; r=0.65).
Hormone-stimulated lipolysis in the isolated, perfused rat heart is thought to be
sensitive to product inhibition by NEFA (Crass III et al. 1975, Stam and Hulsmann 1978,
Severson and Hurley 1982). During hypoxia, if TAG breakdown is stimulated,
intracellular NEFA are likely to increase in concentration in the buffer-perfused heart
due to the decrease in oxidative metabolism, and therefore possibly exert feedback
inhibition on lipolysis.
If albumin is present in the perfusate, NEFA are able to leave the heart and bind to
fatty acid binding sites on the protein. Product inhibition may thus be removed and an
increase in glycerol release would be expected (Fig 6.2). The positive correlation
between myocardial a-glycerophosphate concentration and glycerol release could also be
accounted for by removal of product inhibition of lipolysis by a-glycerophosphate in
providing substrate for re- esterification of intracellular TAG.
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Glycerol release is expressed as nmol.g'^wet wt.min'l
a-glycerophosphate concentration is expressed as p.mol.g"^dry wt.
At the rate of glycerol release observed during severe hypoxia (~90 nmol.g'lmin'l;
Chapter 3), assuming that each glycerol molecule released represents the hydrolysis of
one TAG molecule, 270 nmol.g'^min'l NEFA would remain in the heart. Assuming a
NEFA:albumin molar binding ratio of 2:1 (Goodman 1958), at a flow rate of 10 ml/min,
an albumin concentration of 0.1% would be adequate to bind all NEFA leaving the tissue
and entering the coronary effluent. The effects of an albumin concentration of 0.2% on



























Nicotinic acid is well known to have antilipolytic properties in adipose tissue (Carlson
and Oro 1962) and is though to inhibit lipolysis by decreasing cAMP production
(Butcher et al. 1968; Fig 6.3).
Figure 6.3. The mechanism of action of nicotinic acid.
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The drug was found to inhibit isoprenaline-stimulated glycerol release in the isolated,
perfused rat heart at concentrations ranging from 10 nM to ImM (Christian et al 1968).
However, at a concentration of 1 mM, it had no effect on cAMP release from the heart
during isoprenaline infusion (O'Brien and Strange 1975). The effect of this drug on
isoprenaline-stimulated and hypoxia-stimulated glycerol release was therefore examined
to determine whether myocardial glycerol production is mediated by a mechanism
similar to that in adipose tissue. It is generally assumed that glycerokinase activity in
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the heart is negligible (Challoner and Steinberg 1965, Christian 1968, Jesmok et al. 1977,
Trach et al. 1984, Stam and Hulsmann 1981a). However, the enzyme is known to exist
in heart tissue (Robinson and Newsholme 1967), and glycerol utilization by the dog heart
when arterial plasma glycerol concentrations are raised (ie.during infusion of
isoprenaline) has been demonstrated (Vik-Mo et al. 1979). It should therefore be
possible to label myocardial TAG by infusion of radiolabeled glycerol.
Lactate may be used preferentially as a substrate in the heart (Drake et al. 1980) and
hence may attenuate fatty acid oxidation and also decrease oxidation of a-
glycerophosphate by increasing the NADH/NAD+ ratio, promoting retention of
radiolabeled glycerol in the TAG fraction. As it is generally assumed that the heart is
unable to utilize glycerol, the mechanism of myocardial glycerol uptake and the effects
of insulin on this process have never been studied. Insulin was found to increase
incorporation of radiolabeled glycerol into myocardial TAG. If glycerol is taken up by
the same carrier as glucose, the use of low perfusate glucose concentrations may facilitate
uptake of glycerol. A second group of hearts was prelabelled using the perfusate
composition allowing maximal incorporation of radiolabeled glycerol into TAG using an
identical protocol.
Determination of the specific activity of glycerol released during normoxia,
isoprenaline infusion and hypoxia and comparison with the specific activity of TAG




6.2.1. The influence of albumin on hypoxia-stimulated glycerol release.
Perfusate containing albumin cannot be gassed in the usual way due to foaming of the
solution. Surfactants are often used to prevent foaming but these compounds may affect
membrane structure. The perfusion system illustrated in Figure 6.4 avoids the use of
these compounds. Perfusate containing albumin is pumped by means of a peristaltic
pump into an inverted round- bottomed flask (into which the appropriate gas mixture is
also pumped), and allowed to cover the inside surface of the flask. A large surface area
of the perfusate is thus exposed to the gas, allowing maximal equilibration of perfusate
and oxygen (J Simpson, personal communication). The gassed perfusate is then pumped
in the usual way to the heart using a non-recirculating perfusion system.
Male Sprague-Dawley rats (n=6) were anaesthetized, the hearts removed and
preperfused with albumin-free buffer for 20 min as described in section 2.1.2. Hearts
were then perfused with perfusate containing 0.2% fatty-acid free bovine serum albumin
(Sigma Chemical Company) using the perfusion system shown in Fig 6.4. Hearts were
subjected to normoxia (95%02/5%CC>2) (30 min), followed by hypoxia
(30%O2/65%N2/5%CC>2) (30 min).Coronary effluent was collected at 10 min intervals.
Samples were deproteinized as follows. A portion (1 ml) of each sample was removed
and an equal volume of 0.6 M perchloric acid added. Matched potassium carbonate (200
ul) was added and the samples left on ice for 30 min. Samples were then centrifuged
(1500 g, 4°C, 20 min), after which the supernatant was analyzed for glycerol and lactate.
Oxygen consumption was monitored throughout the experiments. After perfusion, hearts
were freeze-clamped, freeze-dried and analyzed for ATP, CP, glycogen, a-
glycerophosphate, glycerol and TAG as described in Chapter 2.
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6.2.2. The influence of nicotinic acid on glycerol release during isoprenaline
infusion and hypoxia.
Male Sprague-Dawley rats were anaesthetized, the hearts removed and perfused as
described in Section 2.1.2. After the 20 min stabilization period, nicotinic acid (final
concentration as specified for each experiment) was continuously infused (0.1 ml/min)
proximal to the heart. After 30 min nicotinic acid infusion, both nicotinic acid and
isoprenaline (10 nM) were infused simultaneously. Coronary effluent was collected at
10 min intervals and analyzed for glycerol.
A further group of hearts (n=6) was subjected to 30 min normoxia followed by 30 min
hypoxia in the presence of the concentration of nicotinic acid conferring maximal
inhibition of isoprenaline-stimulated glycerol release (100|iM). Coronary effluent was
collected at 10 min intervals and analyzed for glycerol and lactate. Oxygen consumption
was monitored throughout. At the end of the experiment, hearts were freeze-clamped,
freeze-dried and analyzed for ATP, CP, glycogen, a-glycerophosphate, glycerol and
TAG as described in Chapter 2 .
6.2.3. Radiolabelling of myocardial TAG by infusion of [2-3H]-glyceroI.
The first series of experiments served to identify the optimal conditions for labelling
of the myocardial TAG pool. Male Sprague Dawley rats were anaesthetized, the hearts
removed and perfused for a 20 min stabilization period as described in Section 2.1.2.
Subsequently, [2-^H]-glycerol (Amersham ICi/mmol; lmCi/ml) was infused
(0.2uCi/min) for 30 min. Infusion of radioactivity was then stopped and coronary
effluent was collected at 2 min intervals and radioactivity measured as described in
section 2.2.8. Hearts were then freeze-clamped, freeze-dried, the tissue lipids extracted
and separated into fractions as described in section 2.2.7. The amount of [2-3H]-
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glycerol in each lipid fraction and the amount of TAG were measured as described in
sections 2.2.8. and 2.2.6. respectively. The specific activity of the TAG could therefore
be calculated.
The conditions examined to determine the optimum requirements for incorporation of
[2-^H]- glycerol into TAG were as follows:
1. 5.5 mM Glucose (n=3)
2. 5.5 mM Glucose and 5 mM Lactate (n=4)
3. 0.1 mM Glucose and Insulin*(2munits/ml) (n=l)
4. 1.0 mM Glucose and Insulin (2munits/ml) (n=l)
5. 2.0 mM Glucose and Insulin (2munits/ml) (n=2)
6. 5.5 mM Glucose and Insulin (2munits/ml) (n=7)
7.11 mM Glucose and Insulin (2munits/ml) (n=2)
♦Human velosulin, 100 units/ml, 10 ml, Wellcome.
After infusing [2-^H]-glycerol for 30 min, and washing out radioactivity for 10 min,
hearts were subjected to either normoxia (30 min, n=6), isoprenaline (10 nM) infusion
(30 min, n=6) or hypoxia (30 min, n=6). Coronary effluent was collected at 5 min
intervals from t=35 to 60 min and analyzed for glycerol and lactate. [2-3H]-glycerol
and [2-3^0] were measured as described in section 2.2.8.
At the end of the perfusion period, hearts were freeze-clamped, freeze-dried, lipids
extracted and separated into fractions as described in section 2.2.7. [2-^H]-glycerol in
each fraction was counted. The amount of TAG in each heart was measured as described
in section 2.2.6. and the specific activity of TAG thus determined.
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6.3. Results.
The presence of fatty acid free albumin (0.2%) in the perfusate had no effect on
glycerol efflux during hypoxia (Fig 6.5).
Figure 6.5. The influence of hypoxia on glycerol release in the absence and presence
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Glycerol release is expressed as nmol.g'^wet wt. min'* (Mean±SEM)
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In contrast, lactate production after the first 10 min of hypoxia was significantly lower
when albumin was present (Fig 6.6). Total lactate production during the 30 min period
of hypoxia was also significantly lower in the albumin group than in the control group
(75±34 with albumin vs 133112 jimol control; R<0.05, t-test)
Figure 6.6. The influence of hypoxia on lactate release in the absence and presence












Lactate release is expressed as nmol.g'^wet wt. (MeanlSEM)
* P<0.05 vs CONTROL (t-test)
**P<0.01 vs CONTROL (t-test)
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The presence of albumin in the perfusate had no effect on oxygen uptake (2.38±0.04
control vs 2.32±0.07 |imol .g'^min"! with albumin) Myocardial glycogen and a-
glycerophosphate levels after hypoxic perfusion were significantly lower when albumin
was present in the perfusate (Fig 6.7).
Figure 6.7. The influence of hypoxia on myocardial metabolite concentrations in the
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Metabolite concentrations are expressed as |imolg-lwet wt. (Mean±SEM).
*P<0.05 vs CONTROL (t-test)
**P<0.01 vs CONTROL (t-test).
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6.3.2. The influence of nicotinic acid on isoprenaline-stimulated and hypoxia-
stimulated glycerol release.
Nicotinic acid inhibited isoprenaline-stimulated glycerol release in a dose dependent
manner (Fig 6.8).




Glycerol release is expressed as nmol.g'^wet wt. min'l (MeaniSEM)
BASAL ( ) = Glycerol release in the absence of isoprenaline.
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None of the doses of nicotinic acid used fully inhibited Loprenaline-stimulated glycerol
release. At a concentration of 60pM, nicotinic acid caused a 60% reduction in
isoprenaline-stimulated glycerol release (P<0.01). The inhibition was not complete
when the concentration of nicotinic acid was increased to either 80 (iM or 100 |iM.
In addition to its inhibitory action on isoprenaline-stimulated glycerol release, nicotinic
acid (100 (iM) significantly attenuated myocardial lactate production (Fig 6.9) and tissue
a-glycerophosphate concentration (0.85 ±0.1 vs 0.30±0.1 (i.g"^ wet wt with nicotinic
acid (100 |iM); P<0.05, t-test) after isoprenaline infusion.
Figure 6.9. The influence of isoprenaline (10 nM) on lactate release in the absence





















Lactate release is expressed as nmol.g'^wet wt. min'l (Mean±SEM).
★ *P<0.01 vs CONTROL
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The drug had no effect on oxygen uptake during isoprenaline infusion (7.1±0.2 control
vs 7.0±0.5 |i.g~lmin'l with nicotinic acid). In contrast to the effect of nicotinic acid on
isoprenaiine-stimulated glycerol release, the drug had no effect on hypoxia-stimulated
glycerol release (Fig 6.10).
Figure 6.10. The influence of hypoxia on glycerol release in the absence and presence
0 1 0 20 30 40 50 60 70
TIME (min)
a CONTROL
• + NICOTINIC ACID
Glycerol release is expressed as nmol.g'^wet wt. min'l (Mean±SEM)
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The rate of lactate production during hypoxia was not significantly different in the
absence or presence of nicotinic acid at t=40, 50 and 60 min (Fig 6.11).
Figure 6.11 The influence of hypoxia on lactate release in the absence and presence
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Lactate release is expressed as nmol.g'^wet wt. min'l (Mean±SEM).
However, the total lactate release during the 30 min period of hypoxia was significantly
lower in the presence of nicotinic acid (133±12 control vs 101±23 (j-.g'^min"^ with
nicotinic acid; P<0.05, t-test).
Tissue creatine phosphate levels were elevated and a-glycerophosphate levels were
reduced compared with the control group when nicotinic acid was infused during
hypoxia (Fig 6.12).
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Figure 6.12 The influence of hypoxia on myocardial metabolite concentrations in the
absence and presence of nicotinic acid (100 |iM).
METABOLITE
CONCENTRATION 6
ATP CP GLYCOGEN GP TAG
□ CONTROL
□ + NICOTINIC ACID
GP = a-glycerophosphate
Metabolite concentrations are expressed as [imol.g~l\vet wt. (Mean±SEM).
*P<0.01 vs CONTROL
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6.3.3. Radiolabelling of myocardial TAG by infusion of [2-3H]-gIycerol.
Incorporation of [2-^H] glycerol into the neutral lipid fraction of heart tissue under the
various conditions varied (Table 6.1).
Table 6.1. Specific activity of myocardial TAG under various experimental
conditions.
Conditions Specific activity of neutral lipids
(cpm.|imoH)
5.5 mM Glucose 2940
5.5 mM Glucose +5 mM Lactate 6040
0.1 mM Glucose + Insulin
1.0 mM Glucose + Insulin
2.0 mM Glucose + Insulin 22785
11 mM Glucose + Insulin 24385
5.5 mM Glucose + Insulin 28420
(SEMs are not shown for this data due to the small numbers of observations).
Hearts perfused with 0.1 mM and 1.0 mM glucose as the exogenous substrate stopped
beating before the end of the perfusion period and therefore could not be used for further
studies. As the hearts perfused in the presence of 5.5 mM glucose and 0.2 mU/ml
insulin showed the highest incorporation of [2-3H]-glycerol into the neutral lipid
fraction, these conditions were used for subsequent experiments. Radiolabelled glycerol
was readily washed out from the vascular space (Fig 6.13). Incorporation of labelled
glycerol into other lipid fractions also varied (Table 6.2).
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The specific activity of glycerol released during normoxia (Fig 6.14) was not
significantly different than the specific activity of the TAG fraction in the heart at the
end of the perfusion period (Table 6.3).
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Although isoprenaline infusion caused a significant increase in glycerol release, after
the first 5 min of infusion of the drug, the specific activity of the glycerol released (Fig
6.16) was significantly lower than the specific activity of the myocardial TAG (Table
6.3; P<0.01). It therefore appears that isoprenaline stimulates breakdown of a separate,
unlabelled TAG pool.
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Hypoxia also caused a significant increase in myocardial glycerol release, but the
specific activity of the glycerol in the coronary effluent (Fig 6.16) was significantly
lower than the specific activity of the TAG in the heart (Table 6.3; p<0.01).


























TAG concentrations in the heart were not significantly different in any of the groups.
However, the specific activity of TAG after isoprenaline infusion was significantly
higher than after hypoxia (Table 6.3).
Table 6.3. Specific activity of myocardial TAG after normoxia, hypoxia and
isoprenaline infusion.
Normoxia Isoprenaline Hypoxia
[TAG] 0.97±0.2 0.71±0.1 0.73±0.1
Specific activity 39±7 33±3 23±2*
of TAG
* P<0.05 vs isoprenaline (t-test)
[TAG] is expressed as pmol.g'l wet wt (Mean±SEM)
Specific activity of TAG is expressed as cpm nmol~l TAG (MeanlSEM).
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6.4. Discussion.
The presence of fatty-acid free albumin in the perfusate had no effect on glycerol
release during hypoxia. Thus if glycerol release was the result of TAG breakdown,
either lipolysis was not affected by product inhibition, or there was no accumulation of
NEFA within the tissue during hypoxia (tissue NEFA were not measured due to the well
recognized technical difficulties; Van der Vusse and Reneman 1984, Van der Vusse et al.
1985). Previous reports of inhibition of lipolysis used exogenous fatty acids at
concentrations of between 0.25 mM (Stam et al. 1979) and 0.6mM palmitate (Crass et al.
1975) to inhibit glucagon or adrenaline-stimulated lipolysis in the rat heart. During 30
min hypoxia, assuming that 3 moles of NEFA remain in the heart for every glycerol
released, and none of these NEFA are re-esterified, the maximum NEFA concentration in
the tissue would be around 2.7p.M (corresponding to a total glycerol release of ~900
nmol). No effect of this concentration of NEFA on lipolysis has been reported and the
effects of binding of intracellular NEFA to fatty acid binding proteins on lipolysis are
unknown. However, reutilization of glycerol due to activity of glycerokinase would lead
to underestimation of lipolysis when calculated using the amount of glycerol released
from the heart. On the other hand, re-esterification would decrease the tissue NEFA
even further. Thus the conclusion reached from the experiment with regard to the lack
of effect of removal of NEFA by albumin is correct, even if reutilization did take place.
During hypoxia, a large part of the glycerol release appears to be stimulated by a
different mechanism than hormone-stimulated lipolysis (Chapter 5). Inhibition of
hypoxia-stimulated lipolysis by NEFA has not been reported.
Glycogen levels were significantly lower in hearts perfused in the presence of albumin
suggesting that removal of NEFA by albumin led to increased oxidation of glycogen.
However, myocardial TAG concentrations were not reduced after perfusion with albumin
compared with the control group (Fig 6.7), implying that a shift of NEFA from the
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phospholipid to the TAG pool takes place. It is also possible that synthesis of NEFA is
taking place.
Glycerol release during hypoxia was unaffected by nicotinic acid, providing further
support for the hypothesis that a hormone-sensitive lipase is not activated during oxygen
deprivation, as the drug acts by inhibiting cAMP production (Fig 6.3). However, it is
not known whether metabolic changes in the tissue induced by hypoxia eg. decreased pH,
would modify the activity of nicotinic acid.
The effects of nicotinic acid on isoprenaline-stimulated glycerol release conflict with
the results of Christian et al. (1968) who reported decreasing inhibition of isoprenaline-
stimulated glycerol release from the isolated, pefused rat heart when the nicotinic acid
concentration was increased from 10|iM to 100|iM. These workers used a concentration
of 30 nM isoprenaline (rather than 10 nM) to stimulate glycerol release. Additionally,
the Ca++ concentration used in this study was relatively low (1.22 mM). Hron et al.
(1977) reported a lack of response to isoprenaline (1 jxM) at this Ca++ concentration.
Other differences were that the heart rate was controlled by electrical pacing, and that the
rats were killed by decapitation rather than anaesthesia. It is not known whether these
factors affect the response of the tissue to either isoprenaline or nicotinic acid. The
effect of nicotinic acid on isoprenaline-stimulated glycerol release depends on both the
concentrations of both nicotinic acid and isoprenaline and probably also on other
variables.
It has been suggested that the rate of hormone-stimulated lipolysis may be determined
by the availability of a-glycerophosphate to remove product inhibition by re-esterifying
NEFA (Schoonderwoerd et al. 1987). This is consistent with the finding that nicotinic
acid caused a decrease in both myocardial a-glycerophosphate concentrations and
glycerol release during isoprenaline infusion. However, during hypoxia, nicotinic acid
decreased myocardial a- glycerophosphate concentrations but had no effect on glycerol
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release. Thus, in this case, the relationship between tissue a-glycerophosphate
concentration and glycerol release is uncoupled.
Inhibitory effects of nicotinic acid on glycerol production in the isolated, perfused rat
heart have been reported during low flow ischaemia (Trach et al. 1984) and stop flow
ischaemia (van Bilsen et al. 1990) at concentrations of 1 pM and 10 pM respectively.
However, in the latter study the decrease in tissue glycerol concentration brought about
by the presence of the drug was not highly significant (0.05<P<0.1). Adrenaline-
stimulated glycerol release in the ischaemic, isolated, perfused rat heart was inhibited by
nicotinic acid (5 pM) (Brownsey and Brunt 1977), but the fact that the drug had no effect
on basal ischaemic glycerol release was not emphasized.
The drug clearly has inhibitory properties with regard to hormone-stimulated lipolysis
but its effects during hypoxia and ischaemia are controversial. Ischaemia (3 min)
prevented the isoprenaline-induced increase in cAMP formation in the heart (Krause and
England 1982). Thus it seems that the ability of nicotinic acid to inhibit ischaemia-
induced glycerol release has been exaggerated.
Nicotinic acid had no effect on isoprenaline-stimulated increases in cAMP release from
the heart (O'Brien and Strange 1975), suggesting that the drug is unlikely to inhibit
activation of hormone-sensitive lipase in the myocyte. However, direct measurements
of tissue cAMP levels have not been reported.
It is unclear whether nicotinic acid directly inhibits hormone-stimulated lipolysis in the
heart or whether its inhibition of lipolysis is secondary to inhibition of glycolysis (i.e. via
decreased production of a-glycerophosphate)
. As nicotinic acid had no effect on hypoxia- stimulated glycerol release, breakdown of
a- glycerophosphate by acid phosphatase or hydrolysis of phospholipids cannot be ruled
out as sources of glycerol.
The incorporation of [2-3H]-glycerol into TAG implies that glycerokinase activity
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exists in the rat heart contrary to what is generally assumed. Incorporation of glycerol
into TAG was stimulated in the presence of insulin. It is not known whether this
hormone acts by stimulating glycerol uptake, glycerokinase activity, TAG synthesis or
some other mechanism. Insulin inhibits lipolysis in adipose tissue (Jungas and Ball
1963) but was found to have no effect on isoprenaline-stimulated glycerol release from
the isolated, perfused rat heart at a concentration of lOOmU/ml (Christian et al. 1968).
Even in the presence of insulin, less than 1% of the labelled glycerol infused into the
heart was incorporated into TAG. Decreasing the glucose concentration in the perfusate
did not increase incorporation of glycerol into TAG and concentrations of less than 2
mM glucose were detrimental to the heart. The presence of lactate in the perfusate
increased incorporation of glycerol into TAG, possibly by decreasing dehydrogenation of
a-glycerophosphate due to an increased NADH/NAD+ ratio.
The specific activity of the glycerol leaving the heart after five minutes of isoprenaline
infusion was higher than would be expected from simple washout of radioactivity,
suggesting that isoprenaline initially stimulates hydrolysis of radiolabelled TAG. This
was followed by release of glycerol with specific activity lower than that of the
myocardial TAG, implying that either more than one pool of TAG exists in the heart, or
that the glycerol released after the first 10 minutes of isoprenaline infusion is the result of
hydrolysis of newly formed TAG, from phospholipids or from a-glycerophosphate. A
possible role of a-glycerophosphate formed during glycolysis in removing NEFA by re-
esterification, and therefore stimulation of lipolysis is supported. Glycerol release from
the isolated, perfused rat heart is stimulated in the presence of lactate which is likely to
increase the NADH/NAD+ ratio and subsequently the conversion of glyceraldehyde-3-
phosphate via dihydroxyacetone phosphate to a-glycerophosphate (De Groot et al. 1989).
On the other hand, it seems unlikely that a-glycerophosphate stimulates lipolysis by
removing product inhibition (Schoonderwoerd et al.1987) as glycerol release was not
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stimulated when NEFA were removed by albumin. It therefore seems probable that
NEFA are re- esterified with a-glycerophosphate, forming a new, more metabolically
active pool of TAG. TAG can be recovered in lipid droplets (Stein and Stein 1968) and
in lysosomes (Stam et al. 1980) from the heart. The turnover of TAG stored in lipid
droplets has been proposed to be lower than for TAG stored in intracellular organelles
(Stein and Stein 1968). Transfer of TAG from a metabolically inert to a metabolically
active pool may be important in regulation of myocardial TAG homeostasis
(Schoonderwoerd et al. 1989).
Hypoxia-stimulated as well as isoprenaline- stimulated glycerol release appears to
originate from either an unlabelled TAG pool, from phospholipids or from a-
glycerophosphate. Unfortunately this aspect could not be examined further. More
complete labelling of TAG could be achieved by long term infusion of [2- ^H] glycerol
prior to the experiment. However, under these circumstances, it is likely that a
significant amount of glycerol would also be incorporated into phospholipids. Labelling
of this kind would therefore only be useful in determining whether glycerol was of lipid
or of carbohydrate origin.
Obviously, much work is still needed to elucidate the mechanisms and controlling
factors of myocardial TAG metabolism, particularly the changes in TAG metabolism
during hypoxia and ischaemia. The evidence available so far suggests that glycolysis,






The isolated perfused rat heart provides a useful model for quantitative metabolic
studies. Arterial and venous perfusate samples are easily accessible, allowing direct
measurements of metabolism to be made. The double-reservoir perfusion system allows
the oxygen tension of the perfusate supplying the heart to be changed rapidly, enabling
comparison of normoxic and hypoxic metabolism in the same heart. In addition,
cannulation of the pulmonary artery allows anaerobic sampling of coronary effluent for
blood gas analysis and therefore calculation of oxygen uptake.
A disadvantage of the model is that the cellular composition of the whole heart is
heterogeneous. Measurements of metabolism therefore include adipose tissue,
endothelial cells and smooth muscle cells as well as myocytes. Also, progressive
changes in tissue metabolism during perfusion must be taken into account. For
example, insulin is known to affect glucose uptake for up to 30 min after commencing
perfusion (Fisher and O'Brien 1972). The biochemical changes induced by the period of
anoxia between removal of the heart and commencing perfusion must be considered; a
20 min preperfusion period was required within each experiment to allow stabilization of
the rates of lactate and glycerol release from the heart before collection of the first
sample. Also, high flow rates are required to maintain adequate oxygenation of the
tissue as haemoglobin is absent from the perfusate. Creatine phosphate concentration in
the heart was found to decrease after normoxic perfusion, suggesting that even with high
flow rates, oxygenation of the tissue was limited. Hence, this model is more useful for
studying the effects of hypoxia rather than being used as a model of normoxic
metabolism.
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7.2. Metabolism in the Langendorff perfused rat heart during hypoxia.
Myocardial hypoxia was accompanied by decreased oxygen uptake, increased glycerol
and lactate production, increased glycogen breakdown and decreased high energy
phosphate levels. TAG concentrations in the heart were not altered.
Although glycerol release was stimulated during hypoxia, the TAG concentrations of
normoxically and hypoxically perfused hearts were not different. This provides further
evidence in favour of the operation of a TAG-NEFA cycle in the heart during oxygen
deprivation. The TAG-NEFA cycle used only a small percentage (<7%) of the ATP
produced in the heart even during severe hypoxia. Thus, if these results may be
extrapolated to ischaemia, the operation of this cycle probably cannot create
pathologically significant gradients in ATP. However, it should be pointed out that
glycerokinase activity exists in the heart, signifying that measurement of myocardial
glycerol release underestimates the amount of TAG hydrolysis. Hypoxia differs from
ischaemia in many respects (Section 1.3), particularly in that products of metabolism
such as glycerol and lactate cannot readily leave the tissue during ischaemia. Build-up
of lactate causes tissue acidosis, which may in itself affect the metabolism of the heart.
Caution must also be taken in extrapolating results directly from the in vitro situation
where the heart is free from neural and hormonal influences to the in vivo situation.
More than one pool of TAG may exist in the heart (Stein and Stein 1968, Wood et al.
1972, De Groot et al. 1989) and previous studies have shown that ATP may be
compartmentalized within the myocyte (Bricknell and Opie 1978). Glycolytically
produced ATP has been specifically linked with the maintenance of cellular electrolyte
gradients. It is therefore possible that localized TAG-NEFA cycling causing a
significant drain on particular stores of high energy phosphate may be a stimulus for
arrhythmias.
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exhibiting a five-fold increase in TAG concentration compared with hearts from non-
obese rats was only slightly higher than in hearts from the control (non-obese) group
(Chapter 4), and the increase in the proportion of ATP utilized in the operation of the
TAG-NEFA cycle was related to decreased anaerobic ATP production in hearts from
obese rats, rather than increased lipolysis (Table 4.6). This finding is contrary to
previous speculation that TAG levels in the heart may determine the rate of cycling, and
that the cycle may become increasingly significant as a drain of ATP in the compromised
heart (Trach et al 1984). Although basal glycerol release was elevated in hearts from
obese rats, the response to hypoxia was unusual in that glycerol release was stimulated
during the first 15 min of hypoxia but thenceforth declined (Fig 4.3). A higher
proportion of adipocytes in hearts from obese rats may have been the reason for this,
although unfortunately no data are available. The rate of cycling was lower in hearts
from fasted rats than in hearts from fed rats, whereas the TAG levels in hearts from fed
and fasted rats were not different. This provides further evidence that myocardial TAG
concentration is not the major determinant for the rate of the TAG-NEFA cycle.
7.3. The mechanism and source of hypoxia-stimulated glycerol release.
In contrast to isoprenaline-stimulated glycerol release, hypoxia-stimulated glycerol
release could not be inhibited by the ^-adrenoceptor blocking agents atenolol and
timolol. However, pretreatment of rats with 6-hydroxydopamine to deplete stores of
endogenous catecholamines (Hauesler et al. 1969), and subsequent perfusion of these
hearts revealed that approximately 30% of hypoxia-stimulated glycerol release can be
attributed to the action of endogenous catecholamines (Chapter 5). This is contrary to
previous assumptions that hypoxia-stimulated glycerol efflux is entirely due to activation
of a hormone-sensitive lipase in the heart by catecholamines (Hough and Gevers 1975,
Karwartowska-Krynska and Beresewicz 1983).
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Karwartowska-Krynska and Beresewicz 1983).
It is possible that the catecholamine-mediated glycerol release observed during hypoxia
is due to the presence of adipocytes within the heart tissue and that glycerol release from
the myocytes is stimulated by a different mechanism, ^-adrenoceptor function in the
heart did not appear to be affected by hypoxia, demonstrated by comparable amounts of
glycerol release in response to exogenous isoprenaline during normoxia and hypoxia. In
contrast to this, isoprenaline-stimulated glycerol release from isolated myocytes was
attenuated during anoxia (Larsen et al. 1989). This may simply reflect a difference
between anoxia and hypoxia, or alternatively could be interpreted as further evidence that
changes in myocyte glycerol release from the isolated, perfused rat heart are masked by
the response of adipocytes. However, this seems unlikely as in our studies nicotinic
acid, a drug possessing antilipolytic properties in adipose tissue (Carlson and Oro 1966)
was without effect on hypoxia-stimulated glycerol release in the heart (Fig 6.10).
As hypoxia-stimulated glycerol release from the heart is generally assumed to be
mediated by adrenergic mechanisms, little attention has been paid to the role of
myocardial lipases other than hormone-sensitive lipase. It may be that another TAG
lipase, activated during hypoxia independent of catecholamines may play an important
role in the metabolic changes induced by hypoxia.
Alternatively, a new suggestion which emerged from these studies is that hypoxia-
stimulated glycerol release may be the result of breakdown of a-glycerophosphate.
Acid phosphatase activity is known to exist in the heart (Welman and Peters 1976), and
direct breakdown of a-glycerophosphate could therefore lead to glycerol release during
hypoxia. However, the activity of this enzyme in the heart during hypoxia is unknown.
Myocardial a-glycerophosphate concentrations show a positive correlation with glycerol
release from the isolated, perfused rat heart under a variety of conditions (Fig 6.1). It
seems unlikely that a-glycerophosphate production stimulates glycerol release by
166
presence of fatty acid free albumin in the perfusate had no effect on hypoxia-stimulated
glycerol efflux (Fig 6.5). More probable is that re-esterification of NEFA with a-
glycerophosphate may lead to the formation of a more metabolically active TAG pool
and thus stimulate glycerol release.
Another possible source of glycerol released from the heart during hypoxia is
phospholipid. Addition of exogenous phospholipase C to energy-depleted isolated
myocytes during anoxia caused an increase in glycerol release. This effect was absent in
normal (non-energy depleted, normoxic) myocytes, (Myrmel et al. 1989). Endogenous
phospholipase C activity in the heart during hypoxia has not been measured. It has been
demonstrated several times that phospholipid concentrations in the heart are unaltered
after lh of ischaemia (Chien et al. 1984, Das et al. 1986, van der Vusse et al. 1987).
However, a small change in the size of the phospholipid pool could lead to a significant
amount of glycerol release. The phospholipid pool is continually turning over and the
rate of turnover is thought to increase during ischaemia (van der Vusse et al. 1987).
Determination of the origin of glycerol released during hypoxia by labelling
myocardial TAG via short-term infusion of [2-^H]-glycerol has proved to be
complicated, probably due to the existence of more than one TAG pool. Long-term pre-
labelling of TAG by administration of radiolabelled glycerol in vivo could be used to
ensure labelling of all TAG pools. However, the label would also be incorporated into
phospholipids, removing some of its specificity.
Perfusion with radiolabelled fatty acids bound to albumin is another possibility for
measurement of the rate of lipolysis, although re-incorporation of NEFA into the TAG
pool during TAG-NEFA cycling would make interpretation difficult as this would lead to
underestimation of the rate of lipolysis. Again the label would be incorporated into
phospholipids as well as TAG.
Selective labelling of a-glycerophosphate by perfusion of hearts with radiolabelled
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glucose would be complicated due to dilution of the label with glycogen-derived a-
glycerophosphate. Measurement of the relative activities of TAG lipases,
phospholipases, acid phosphatase and glycerokinase during hypoxia would provide more
information about potential sources of glycerol. However, it is customary to measure
enzyme activities under optimal conditions, and inhibitory or stimulatory factors could be
removed during the preparation of the hearts before measurements are made. This
method could not be used for the study of enzyme activities during ischaemia as the
reintroduction of oxygen causes as many biochemical changes as ischaemia itself.
Whether similar problems could arise on re-oxygenation after hypoxia remains to be
seen.
Clearly a combination of experiments are needed to gain accurate information about
the origin of the glycerol released from the heart during hypoxia.
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* Possible sources ot glycerol
Flux through the pathways is indicated by the width of the arrows.
7.4. Conclusion.
The major findings of this thesis are as follows:
1) The operation of the TAG-NEFA cycle in the isolated, perfused rat heart during
hypoxia does not cause a major depletion of ATP supplies.
2) Myocardial TAG concentrations have little influence on the amount of energy utilized
in the operation of the TAG-NEFA cycle during hypoxia.
3) Glycerol may be reutilized in the heart by the action of glycerokinase.
4) The majority of the glycerol release during hypoxia is mediated by non-adrenergic
mechanisms and does not necessarily originate from TAG.
Thus, the results from this thesis suggest that rather than being detrimental to the heart,
the TAG-NEFA cycle may play an important role in minimizing build up of NEFA
concentrations during oxygen deprivation. Increased concentrations of NEFA and their
metabolites may be harmful to the heart during oxygen deprivation (Kurien and Oliver
1970). Thus, contrary to its operation being harmful to the oxygen-deprived
myocardium, the TAG-NEFA cycle may provide some protection against arrhythmias.
Lipolysis in the heart during hypoxia is mediated by different mechanisms than in
adipose tissue, and myocardial glycerol release should no longer be used as a measure of
hypoxia-stimulated lipolysis. Glycolysis and lipolysis in the heart appear to be closely
linked, glycolysis providing a -glycerophosphate for re-esterification of NEFA. More
work is needed to elucidate the mechanisms involved in stimulation of glycolysis and
lipolysis and their interaction during hypoxia, and also to examine the extent and role of
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